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Abstract 
Fibroblast activation protein (FAP) is a cell-surface serine protease which 
promotes invasiveness of certain epithelial cancers. In particular, the heightened 
expression of FAP in tumor cells and the ability of FAP to degrade major components 
of the extracellular matrix such as type I collagen makes it attractive as a target for anti-
cancer therapeutics. FAP is active only when it is in the form of a dimer. Moreover, 
FAP also can heterodimerize with dipeptidyl peptidase-IV (DPP-IV) to facilitate tumor 
cells invasion. Despite the importance of FAP to cancer and other disease processes, the 
mechanism that regulates FAP homo- and heterodimerization, as well as its relation to 
prolyl peptidase activity is not completely understood. Transmembrane (TM) domain is 
found to be a key mechanism to regulate homo- and heterodimerization in several 
transmembrane receptors. Here, I investigate key residues in the FAP TM domain that 
may be significant for FAP homo- and heterodimerization. Using the TM-CYTO as a 
mimic for the full-length FAP in the AraTM assay, I found mutations to predicted TM 
interfacial residues (G10L, S14L, and A18L) in a small-X3-small motif, which has been 
shown previously to promote TM dimerization, reduced FAP TM-CYTO dimerization 
relative to wild type, whereas predicted off-interface residues showed no significant 
change in dimerization from wild type. The results indicate the predicted small-X3-
small dimer interface stabilize the FAP TM-CYTO homodimer. Likewise, 
heterodimerization studies using the DN-AraTM assay between FAP and DPP-IV 
indicate that heterodimerization occurs; there is no preference in terms of TM-mediated 
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heterodimerization between FAP and DPPIV. In terms of FAP exopeptidase activity 
when overexpressed in HEK293 cells, the interfacial TM residue G10L significantly 
decreased FAP exopeptidase activity by more than 25%, and also reduced cell-surface 
expression relative to other interfacial residues (S14L, A18L). Collectively, my results 
suggest FAP homodimerization is important for both trafficking and protease activity, 
and is dependent on a specific, TM small-X3-small interface. In addition to the TM 
domain, I also investigated the role of hydrophobic residues (W728, F724 and Y239) 
buried in the homodimer interface of the FAP ectodomain crystal structure in terms of 
FAP homodimerization and exopeptidase activity. Compared to the off-interface 
A657V mutant, W728A, F724A and Y239A FAP constructs exhibit decreased 
exopeptidase activity (74%, 75% and 59% less exopeptidase activity than wild-type, 
respectively), whereas no decrease in exopeptidase activity occurs for the A657V 
mutant. Mutants W728A and Y239A also impaired trafficking to the cell surface when 
overexpressed in HEK293 cells. Collectively, my results indicate that change in 
dimerization observed for mutants W728A and Y239A affect both enzymatic activity as 
well as trafficking.  
In summary, TM interfacial residues (G10L, S14L, and A18L) in a small-X3-
small motif and hydrophobic residues (W728, F724 and Y239) buried in the homodimer 
interface of the FAP ectodomain are important for FAP homodimerization, 
exopeptidase activity, and localization. My studies provide the insight to understand 
mechanism of FAP homo- and heterodimerization relating to enzymatic activity and 
protein localization. They can be a guideline to design an efficient drug delivery system 
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for anti-cancer therapies based on FAP activity. Designed FAP-selective peptides are a 
next interesting part that I want to use as protease-responsive peptides in delivery 
systems for targeting cancer cells and accessing the tumor microenvironment (TME).
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Chapter 1 
 
Introduction 
 
1.1: Background and motivation 
 Tumor development is multistep-processes to transform normal cells to 
malignant cells. The biological consequences of tumor progression are involved with 
five biological processes; uncontrollable cell proliferation, increase of ability to acquire 
genetic alterations due to deregulated DNA repair, ability to grow in adverse conditions 
due to decreased apoptosis, capacity to invade tissues locally and form distant 
metastases, and angiogenesis that is the ability to activate the formation of new blood 
vessels (1). However, tumor cells are surrounded with a rich microenvironment 
composed of resident fibroblasts, endothelial cells, pericytes, leukocytes, and extra-
cellular matrix (2). The tumor stroma is a crucial part for growth and progression of 
cancer initiation, especially during a malignant state. Cancer cells in this state have the 
capacity of invading surrounding tissue and seeding metastases via lymphatic or blood 
vessel through the tumor stroma. These processes require protease activity to remodel 
the extracellular matrix (ECM) surrounding tumor cells. Remodeling ECM by proteases 
increases tumor invasion and metastasis. Degradation of ECM by theses proteases 
interferes with the adhesion between tumor cells and adjacent cells or matrix (3).        
 Cell surface proteases provide a critical role in facilitating cell invasion into the 
ECM. These proteases associate to form invadopodia at plasma membrane protrusions 
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in order to contact and dissolve the matrix. Invadopodia can degrade a variety of 
components in ECM including fibronectin, laminin and type I collagen (4). The cancer-
associated fibroblast (CAF) in the tumor stroma provides several proteases and growth 
factors for ECM degradation, angiogenesis and metastasis. Generally, transmembrane 
glycoproteins consisting of extracellular domains, a transmembrane domain and a short 
cytoplasmic tail are located in invadopodia to provide ECM degradation. Matrix 
metallo-proteinase, DPPIV, Fibroblast Activation Protein (FAP)/Seprase, meprin and 
GBase are examples of transmembrane glycoproteins in stromal components that are 
related to degradation and metastatic spread of tumor cells (5). 
FAP is expressed in activated stromal fibroblasts of more than 90% of the tumor 
mass in lung, colorectal, and breast carcinomas (6). FAP expression is difficult to detect 
in non-diseased adult organs, benign, and premalignant epithelial lesions but is greatly 
upregulated in sites of tissue remodeling including liver fibrosis, lung fibrosis, 
atherosclerosis, arthritis, tumours and embryonic tissue (7). FAP has been studied as a 
cell surface marker for proliferating mesenchymal cells (8). Research suggests that FAP 
may play a critical role in altering the microenvironment of tumors and promoting 
tumor growth through degradation of ECM such as collagen, thereby enhancing 
metastatic potential by creating “space” for the solid tumor to migrate. Therefore, FAP 
is an interesting potential target enzyme for developing a drug delivery system for 
cancer therapies. 
To design an efficient drug delivery system for anti-cancer therapies, we must 
consider the critical barrier of effectiveness to deliver drugs to solid tumors due to the 
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high density of the extra cellular matrix (ECM)-rich microenvironment surrounding the 
tumor, otherwise referred to as the tumor microenvironment (TME) (9). The tumor 
environment (TME) limits diffusion of drugs to the tumor due to its enhanced density 
and reduced permeability. In tumor cells, newly formed vessels are more porous than 
normal vessels; previous studies have shown 100 nm particles can access the 
vasculature-interface (10), but nanoparticles (NPs) 10 nm or less are required to enter 
the TME.  Due to the density of collagen-rich ECM in this area, FAP is an appealing 
protease that helps to overcome this barrier for the drug target.   
We are, therefore, focusing on understanding the structural elements of FAP 
involved in homodimerization and heterodimerization, identifying, designing and 
synthesizing specific substrates to further test specific exopeptidase as well as 
endopeptidase activity. This insight is leading to development of a drug delivery system 
based on FAP, which is over-expressed in tumor stoma cells, but not in normal cells or 
solid tumors; exploiting FAP protease activity will enable selective degradation of 
nanoparticle, gel or other drug formulations at the vasculature-TME interface to 
generate particles of an appropriate size (< 10 nm) capable of accessing the TME and 
solid tumor (11) as shown in Figure 1.1. 
Currently, we used the AraTM and and the DN-AraTM assay as a bacterial 
reporter system for understanding the biological function of FAP in both 
homodimerization and heterodimerization. We identified important interfacial residues 
within the FAP transmembrane (TM) helix involving in homodimerization and 
proteolytic activities. The heterodimerization between FAP and DPPIV also is an 
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interesting point for us to investigate the formation of these two proteases. TM domain 
might play a significant role to drive heterodimerization. Using AraC, we were 
successful in identifying the interfacial residues have an effect on FAP 
homodimerization and localization. However, other regions in the extracellular domain 
(ECD) of the FAP full-length protein may also affect enzyme homodimerization. 
Therefore, we also studied the full-length FAP that is expressed in the HEK cells and 
we have designed a FAP-Selective Peptide for use as a protease-responsive peptide to 
examine its endopeptidase activity. Understanding on a molecular level of the residues 
that can stabilize the FAP dimeric form, which is important for FAP endo- and 
exopeptidase activity is our expectation. Moreover, a model to design a peptide-linked 
gel based on endopeptidase activity is a novel idea for a delivery system to target cancer 
cells and access the TME. These goals will provide the insight to guide strategies to 
design an efficient drug delivery system for anti-cancer therapies based on FAP activity.  
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Figure 1.1.  The hybrid nanocarriers (HNC) are a potential drug delivery system for 
targeted cancer treatment. The pathway of the drug-loaded nanoparticle and specific 
peptide tether penetrates through the leaky vasculature and accessing the tumor 
environment (TME) interface by size of HNC. FAP activity over-expressed in TME-
tumor degrades HNC to re-size and release smaller nanoparticles that can be diffused 
through TME. Then, Legumain that is released by the solid tumor and low pH condition 
in that area provide releasing of drug to target only cancer cells (11).  
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1.2: Fibroblast Activation Protein (FAP) or Seprase 
 1.2.1: Structure 
FAP is a type II cell surface glycoprotein that has the bulk of the protein, 
including the C-terminal, facing the extracellular space. The structure of FAP contains 
an extracellular domain comprised of a catalytic domain characteristic of serine 
proteases, a transmembrane domain (TM domain), and a short cytoplasmic tail as 
shown in Figure 1.2 (12). Three-dimensional structure of FAP shown as ribbon diagram 
from pdb accession code 1Z68 represents the dimeric form between extracellular 
domains (Figure 1.3). Within the active site of the enzyme, serine (S624), aspartate 
(D702), and histidine (H734) are arranged to form an inverted catalytic triad, where 
serine serves as the nucleophilic amino acid and it defines FAP as a serine protease (13-
16). The catalytic triad is located at the interface of the -propeller and -hydrolase. 
The arrangement of three amino acids: histidine, serine, and aspartic acid in the order 
nucleophile-acid-base is a characteristics of the -hydrolase (17). Moreover, the serine 
624 mediates both the dipeptidyl peptidase and endopeptidase activities (14, 18). The -
propeller domain acts as a gating filter during catalysis by letting small peptide 
substrates into the active site. It prevents accidental proteolysis of large protein in the 
cytosal. Therefore, the -propeller domain may serve as a gate to selectively filter 
protein access to the catalytic triad (13, 17, 19) 
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Figure 1.2 FAP structure. FAP shows a type II integral membrane protein with a large 
C-terminal extracellular domain including 7-Bladed -propeller and -hydrolase 
domain (20). 
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Figure 1.3 Three-dimensional structure of FAP. The structure reveals the 
dimeric structure of FAP. Two extracellular domains, each composed of a -propeller 
domain (represented in blue) and an -hydrolase domain (represented in green) come 
to form a dimer. The catalytic triad consists of Serine 624 (purple), Aspartic acid 702 
(cyan) and Histidine (yellow) (12).   
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1.2.2: Classification and biochemical aspects 
FAP is grouped in the subfamily S9b of the peptidase family S9 (prolyl 
oligopeptidaes family) and clan SC which is known to cleave prolyl peptide (Pro-Xaa) 
bonds (21). This group contains four enzymatic members; DPPIV, Fibroblast activation 
protein (FAP), DPP8, and DPP9 which are able hydrolyse a prolyl bond from the N-
terminus of the protein. Unlike others in the same family, it has gelatinase and, possibly, 
collagenase activity (22, 23). As shown in evidence using zymography, FAP was 
demonstrated to cleave gelatin and collagen type I, but was not able to cleave human 
fibronectin, laminin, or collagen IV (22). This predominant enzymatic role for type I 
collagen (CN-I) (22, 24) and -antiplasmin (2-AP) (25) is not exhibited by other serine 
proteases in the same family, such as dipeptidyl peptidase IV (DPPIV/CD26) and the 
related type II transmembrane propyl serine peptidases. Therefore, FAP is a proline 
specific protease that exhibits endopeptidase activity as well as exopeptidase activity 
(13, 26). Restriction in expression pattern and doubled enzymatic activities of FAP 
make it useful for several applications. 
 FAP is an active dimer of N-glycosylated 97 kDa subunits. A soluble, 
homodimeric form of FAP is shed from the plasma membrane, having been also 
identified as the soluble form of Antiplasmin Cleaving Enzyme (APCE) that is required 
for gelatinase and dipeptidyl peptidase activity (27). Previous work has focused on 
whether homodimer formation is required for FAP activity using gelatin zymography 
and size exclusion chromatography. The study of FAP soluble form showed that the 
homodimeric enzyme cleaves gelatin, the fluorogenic exopeptidase substrate Ala-Pro-7-
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amino-3-trifluoromethylcoumarine (AFC) and the fluorogenic exopeptidase substrate, 
Z-Gly-Pro-7-Amino-4-Methylcoumarin (AMC). However, no such activities against 
any of these substrates was observed from the monomer (27). Moreover, serine protease 
inhibitors, including diisopropyl fluorophosphates (DFP) and PMSF, block the 
gelatinase activity of dimeric, soluble FAP by binding in its active site. The previous 
work (15) showed that the FAP was affinity-labeled by [3H] DFP, but an inactive 97 
kDa subunit was not. Treatments with acid, heat, or cysteine and histidine modifying 
agents also cause the loss of proteolytic activity because of the dissociation of a dimeric 
form of soluble FAP. Collectively, these studies suggest that the dimeric enzyme in the 
FAP soluble state has protease activities (15). However, efforts to understand the 
structure/function relationship of homodimeric, membrane bound FAP are limited. 
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Chapter 2 
 
A specific, transmembrane interface regulates 
fibroblast activation protein (FAP) 
homodimerization and exopeptidase activity 
Fibroblast activation protein (FAP) is a cell-surface serine protease which 
promotes invasiveness of certain epithelial cancers and is therefore a potential target 
for cancer drug development and delivery. Unlike dipeptidyl peptidase IV (DPPIV), 
FAP exhibits prolyl endopeptidase activity and is active as a homodimer with specificity 
for type I collagen. The mechanism that regulates FAP homodimerization and its 
relation to prolyl endopeptidase activity is not completely understood. Here, we 
investigate key residues in the FAP TM domain that may be significant for FAP 
homodimerization. Mutations to predicted TM interfacial residues (G10L, S14L, and 
A18L) comprising a small-X3-small motif reduced FAP TM-CYTO dimerization relative 
to wild type as measured using the AraTM assay, whereas predicted off-interface 
residues showed no significant change from wild type. The results implied that the 
predicted small-X3-small dimer interface affect stabilization of FAP TM-CYTO 
homodimerization. Compared with FAP wild-type, the interfacial TM residue G10L 
significantly decreased FAP endopeptidase activity more than 25%, and also reduced 
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cell-surface expression relative to other interfacial residues (S14L, A18L). Thus, our 
results suggest FAP dimerization is important for both trafficking and protease activity, 
and is dependent on a specific TM interface 
2.1:   Introduction  
Seprase or Fibroblast Activation Protein (FAP) is a type II integral membrane 
serine peptidase. It is a cell surface glycoprotein that contains an extracellular domain 
comprised of a catalytic domain characteristic of serine proteases, a transmembrane 
domain (TM domain), and a short cytoplasmic tail (1). FAP is overexpressed in tumor 
stoma in lung, colorectal, and breast carcinomas, and overexpression of this protein is 
also associated with tissue remodeling in liver fibrosis, lung fibrosis, artherosclerosis, 
and arthritis (2). Unique from other proteases in the same family such as dipeptyl 
peptidase-4 (DPPIV), FAP has gelatinase and collagenase activity, with an ability to 
process type I collage after pre-cleavage by matrix metalloproteases (MMPs) (3, 4). 
Thus, the unique endo- and exopeptidase activity of FAP and direct relevance to disease 
makes it an interesting protein in terms of understanding how both proteolytic activities 
relate to both development and disease. 
An open question in terms of membrane-bound FAP activity is the 
interrelationship between dimerization, cell-surface localization and protease activity. 
Previous studies for DPPIV have indicated that hydrophobic TM residues such as 
leucine and alanine can play a key role in promoting dimer formation, although the 
nature of the specific mutation to a disruptive proline was required for loss of 
dimerization and exopeptidase activity versus other types of mutations such as glycine 
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(5). Additionally, studies on a soluble form of FAP indicate that renatured protein 
migrate as both monomer and dimer, with only the dimeric form exhibiting gelatinase 
activity (6). Thus, whether TM dimerization occurs, and how it affects FAP protease 
activity in the context of membrane-bound FAP, remains an open question.  
Here, we characterize the dimerization and protease activity of membrane bound 
FAP, with particular focus on the role of the TM domain in dimerization. Using 
AraTM, we identified a specific TM interface responsible for TM-CYTO dimerization. 
In the full-length receptor, we demonstrate residues in the identified TM-CYTO 
interface reduce exopeptidase activity and cell-surface localization when overexpressed 
in a HEK293T cell line. Thus, our results indicate the importance of a specific TM 
interface in FAP dimerization that affects both trafficking and exopeptidase activity. 
2.2:   Materials and Methods 
2.2.1 Materials 
 The Human Embryonic Kidney (HEK) 293T/17 cells were purchased from 
American Type Culture Collection (ATCC). DMEM was supplied from Mediatech, Inc 
(Corning Subsidiary). Fetal bovine serum was from GE healthcare life sciences. 
Lipofectamine 2000 was obtained from Life Technologies. All restriction enzymes were 
purchased from New England BioLabs. QuickChangeII site directed Mutagenesis kit 
for site-directed mutagenesis was from Agilent technologies. H-Ala-Pro-AFC for 
enzyme activity test was obtained from Anaspec. Inc. EZ-Link Sulfo-NHS-Biotin, BS
3
 
crosslinker and Streptavidin Magnetic Beads were purchased from Themo scientific. 
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Unless otherwise stated, standard molecular biology techniques were used for 
subcloning, mutagenesis and DNA preparation. 
2.2.2:   Methods 
2.2.2.1: AraTM Homodimerization Assay 
The AraTM assay is a system for measuring homodimerization of TM and 
soluble receptor domains (7). This approach uses the E. coli AraC transcription factor 
fused to a TM-containing receptor fragment of interest to investigate how specific 
domains and residues within a receptor contribute to dimerization in cell membranes. 
The chimeras contain the full-length maltose-binding protein (MBP), including its 
native signal peptide sequence, at the N-terminus, and the AraC transcription factor in 
the C-terminus. A synthetic, codon-optimized sequence corresponding to the FAP TM-
CYTO was generated using oligo-directed assembly of designed oligonucleotides 
corresponding to the FAP TM-CYTO sequence, which were then amplified using 
specific primers that included SacI and KpnI to generate the insert. The TM-CYTO was 
then ligated into pAraTM as a SacI-KpnI fragment in-frame with the C-terminal AraC 
and N-terminal MBP. All FAP chimera contained a poly-L-proline type II (PPII) helix 
linker between FAP TM-CYTO and AraC to reduce AraC steric hindrance at the 
membrane; PPII is often found at the edges of α-helices in domain linker regions, which 
makes it appropriate as a linker (8). Quantification of GFP signal for FAP TM-CYTO 
wild-type and mutants was performed essentially as described previously; each signal 
represents an average of at least 5 independent measurements (7). Proper integration of 
FAP wild-type and mutant TM-CYTO chimera in the E. coli inner membrane was 
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confirmed using a maltose complementation assay, which was performed essentially as 
described previously (7).  
2.2.2.2: Immunoblotting 
AraC-chimera expression was detected from whole-cell extracts as described 
previously (7). Plasmids containing FAP TM insert were transformed into MBP-
deficient MM39 cells and cultured at 37C for 24 hours. The 5 selected colonies were 
culture grown to A600 of 0.6 at 37C in a shaking incubator at 200 rpm. 24 L of cell 
lysate was mixed with 6 L of 5x Lammeli sample buffer with -mecaptoethanol, 
heated for 10 minutes at 90C, then loaded onto a 12% acrylamide gel. Samples were 
analyzed at  120V using MES running buffer, then transferred to a nitrocellulose 
membrane (Amersham Biosciences Hybond ECL) for 90 min, blocked with 5% milk in 
TBST for 1 h at room temperature, then incubated with 1,000x dilution of HRP-
conjugated anti-MBP monoclonal antibody (NEB) at 4C overnight. Membranes were 
developed using a chemiluminescent substrate (GE) for 5 minutes before they were 
imaged using a Typhon imager.  
For immunoblotting of full-length FAP wild type and mutants expressed in HEK 
293T cells, cells were collected after transfection for 48 hours. The cell lysate was 
mixed 5x Lammeli sample buffer without -mecaptoethanol. Samples were loaded onto 
8% SDS- acrylamide gel and run in SDS running buffer, then transferred to 
nitrocellulose membranes as described above. The transferred membrane was incubated 
with 1,000x dilution of anti-HA monoclonal antibody (BioLegend) at 4C overnight, 
followed by washing and incubation with 1,000x dilution of mouse IgG secondary 
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antibody (NEB) for 1 hour. After incubating the membrane with a chemiluminescent 
substrate (GE) in dark for 5 minutes, it was exposed with an autoradiography film 
(Carestream Kodak BioMax light film) and developed using a film processor (SRX-
101A, Konic Minolta).  
 
2.2.2.3: Cell transfection, expression and dipeptidyl peptidase assay 
 The FAP-pDrive plasmid was a kind gift of Prof. Ellen Puré (University of 
Pennsylvania). The full-length FAP was amplified from this plasmid with forward 
primer containing SacI (5’-GAGCTCATGAAGACTTGGGTAAAAATCGTATT-3’) 
and reverse primer containing KpnI, HA tag and stop codon (5’- GGTACCTT 
AGGCGTAGTCGGGCACGTCGTAGGGGTAGTCTGA CAAAGAGAAACA-3’) 
and cloned into plasmid mGFP-N2 (Biosignal Packard). HEK293T cells were 
transfected using Lipofectamine 2000 reagent (Life Technologies) according to the 
manufacturer’s instructions. Each transfection was carried out on a 6-well plate with 4 
g of plasmid. After 48 hours, cells were collected, washed with 1X PBS and lysed 
with 1X RIPA buffer without serine protease inhibitors. The 1X RIPA contains (20 mM 
Tris pH 7.5, 150 mM NaCl 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1 mM -
glycerolphosphate, 2.5 mM Sodium pyrophosphate).  
To measure FAP activity, the cell lysate was incubated with H-Ala-Pro-AFC 
(500 M; AnaSpec) for 5 minutes (4). Hydrolysis product concentration for both FAP-
transfected and mock-transfected samples was determined from fluorescence emissions 
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intensity measurements (excitation wavelength at 400 nm, emission wavelength at 510 
nm) monitored over the course of 1 hr at 37C.  
2.2.2.4: Immunoprecipitation 
The transfected cells containing both wild-type FAP and mutants were collected 
and washed 3 times with 1x PBS pH 8.0 before they were resuspended at a 
concentration of 10
6
 cells/mL in PBS (pH8.0). Cell surface, membrane-bound FAP was 
then labeled with EZ-Link Sulfo-NHS-Biotin (Thermo scientific) according to the 
manufacturer’s instructions. After incubation for 30 minutes at room temperature, 
excess biotin reagent and byproducts were quenched and removed by washing with 1x 
PBS + 100 mM glycine. 0.5 mg of pre-washed streptavidin magnetic beads (Thermo 
scientific) was then added to 300 L of Sulfo-NHS-Biotin labeled cells resuspended in 
PBST (pH 7.5). After incubating for 1 hour at room temperature, the beads were 
washed with PBST (pH 7.5).  60 l of 5x SDS-PAGE reducing sample buffer 
containing -mercaptoethanol was added to the tube and the sample was heated at 
100˚C for 5 minutes. The supernatant containing FAP transmembrane protein was 
separated from the beads using a standard magnet. 
2.3:   Results 
2.3.1: A conserved, small-X3-small motif is required for FAP TM-CYTO 
dimerization 
Through a TM domain sequence alignment for FAP orthologues (Figure 2.1A), 
we identified a conserved TM domain sequence motif among mammalian species 
comprised of small and polar residues with 4-residue periodicity. This pattern of small 
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residues, referred to as a small-X3-small motif, has been shown previously to be an 
overrepresented motif present in a diverse array of TM helices, where it contributes to 
the stability of TM helix dimers by facilitating a specific dimer packing interface. The 
predicted small-X3-small packing interface present in FAP is highlighted in Figure 
2.1B, with residues G10, S14 and A18 on the predicted dimer interface shaded light 
grey for emphasis. 
 To test whether this putative interface is capable of stabilizing a FAP TM-
mediated dimer, we subcloned the TM-CYTO of FAP into the AraTM system and 
quantified extent of dimerization for a series of mutants on-interface (G10, S14, A18) as 
well as other small residues that lie off-interface (A12, C23). In AraTM, constructs are 
fused to the bacterial transcription factor AraC and expressed in the E. coli inner 
membrane; by introducing a reporter plasmid expressing GFP under the control of the 
araBAD promoter, the extent of dimerization of a given construct can be quantified in 
terms of the level of expressed GFP per cell. The expression membrane integration of 
all chimeras was confirmed by a maltose complementation assay and immunoblotting 
with an anti-MBP antibody (Figure 2.2 and 2.3). Comparing mutations on- and off-
interface, disruptive mutations on-interface (G10L, S14L, A18L) all cause a significant 
disruption (> 15%) of FAP TM homodimerization, whereas off-interface mutations 
(A12, C23) show only a negligible change in dimerization (< 5%) (Figure 2.4). 
Moreover, a conservative substitution (S14G) enhances dimerization relative to wild-
type, again indicative of this specific TM interface (G10L, S14L, A18L) as important 
for dimerization. Collectively, these results indicate that the small-X3-small motif 
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(G10L, S14L, and A18L) in the transmembrane domain of FAP is important for FAP 
TM-CYTO dimerization in cell membranes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1:  A conserved, transmembrane dimerization motif in the FAP TM. (A) 
FAP TM domain sequence alignment among different mamalian species showns a 
highly conserved small-X3-small motif (G10, S14, A18) in the transmembrane region 
(the shaded grey box). (B) The FAP TM helix, highlighting small and polar residues 
(G10, S14, A18) in the predicted dimer interface. 
(A) 
(B) 
(C) 
(A) 
(B) 
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Figure 2.2: Maltose complementation test for wild-type and mutant expression in 
AraTM system. Wild-type and mutant AraTM chimeras were expressed in MalE-
deficient MM39 cells and streaked on a 0.4% maltose M9 plate. Each construct is 
properly integrated into the inner membrane of E. coli, as indicated by robust growth on 
the 0.4% maltose M9 plates similar to the positive control (pTrcRSF containing MBP-
AraC chimera). As expected, no growth is observed on the negative control (only 
pTrcRSF). 
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Figure 2.3:  Western blotting for FAP wild type and mutants in AraTM constructs.  
Western blotting with an anti-MBP monoclonal antibody (HRP-conjugated) confirmed 
expression of mutant constructs. The expected size of protein expression is around 67 
kDa.   
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Figure 2.4: AraTM results to identify residues responsible for FAP dimer 
formation. We propose site-directed mutagenesis on interfacial mutants will alter FAP 
TM homodimerization, whereas mutations to off-interface residues will not. AraTM 
results for on- and off-interface residues of FAP. The results presented fractional 
differences in GFP signal from wild type. Negative values represent mutations that 
disrupt FAP homodimerization, especially mutations in interface residues. 
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2.3.2: Membrane-bound FAP is expressed at the surface of HEK293 cells in an 
active form 
To demonstrate that full-length, membrane bound FAP is expressed in HEK293 
cells, we tested exopeptidase activity against transfected HEK293 cells containing full-
length FAP. Comparing expression at 24 and 48 hours, we observe a greater extent of 
both FAP monomer (97 kDa) and FAP dimer (170 kDa) after 48 hours. Furthermore, 
exopeptidase activity against H-Ala-Pro-AFC increases by 40% at 48 hours expression 
(Figure 2.5A). To confirm this activity is specific to FAP, transfection of the inactive 
mutant FAP S624V, in which the catalytic serine is removed, shows no significant 
exopeptidase activity. The expression level of all FAP mutants and wild-type is not 
significantly different at 48 hours as well. Therefore, FAP wild-type is expressed in an 
active, membrane-bound form in HEK293T cells, and mutants are expressed at 
comparable levels to wild-type (Figure 2.5B). 
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Figure 2.5: Expression FAP WT versus mutants. (A) Western blots for wild-type 
FAP expression in HEK293T cell show similar whole-cell expression levels for FAP 
wild-type and TM domain mutants between 24-48 h. The FAP monomer is 97 kDa. 
Tubulin was used as a marker showing protein expression level. (B) Consistent with 
increased expression at 48 h post-transfection, increased exopeptidase activity using H-
Ala-Pro-AFC as a substrate was measured 48 h post-transfection. Overexpression of an 
inactive FAP mutant (S624V) does not show specific exopeptidase activity, indicating 
the observed signal is specific to overexpressed FAP.  
(A) 
(B) 
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2.3.3: Interfacial transmembrane mutations reduce exopeptidase activity 
To determine dipeptidyl peptidase activity between FAP wild-type and TM 
domain mutants, a saturating concentration of the substrate H-Ala-Pro-AFC was added 
to transfected HEK293T cells. In particular, the interfacial mutation G10L causes a 
significant (27%) decrease in exopeptidase activity, whereas the other 2 interfacial 
mutants (S14, A18) do not show a significant change from wild-type (Figure 2.6). The 
decrease for G10L is significant, although it does not exhibit complete inactivation as 
the catalytically-inactive S624V mutant does. Thus, our results indicate that mutations 
to the key, interfacial residue G10L important in TM-CYTO dimerization also 
significantly reduces exopeptidase activity, and are consistent with TM-CYTO 
dimerization playing a role in regulating FAP exopeptidase activity.  
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Figure 2.6: Interfacial TM mutation G10L reduces exopeptidase activity. Relative 
changes in exopeptidase activity for mutant and wild-type FAP indicates interfacial 
mutant G10L significantly reduces exopeptidase activity as compared with wild-type. 
Error bars represent the standard error for an average of 4 independent measurements. 
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2.3.4: Interfacial transmembrane mutations reduces cell surface localization 
In order to determime what effect TM-mediated dimerization and exopeptidase 
activity have on FAP trafficking, the relative levels of FAP expression at the cell 
surface were compared to total FAP expression for each of the TM and ectodomain 
mutants. Specifically, surface FAP was labeled using NHS-biotin, solubilized and 
separated using streptavidin magnetic beads (9). Relative FAP levels in the purified, 
surface extract was determined by western blotting using an anti-HA antibody. As 
shown in Figure 4, compared to wild-type, TM mutant G10, which reduces 
exopeptidase activity (Figure 3C), shows a significant decrease in cell surface 
localization, whereas TM mutants S14 and A18 have similar cell surface expression 
levels to wild-type. Similar to G10L, the catalytically-inactive S624V mutant also has 
reduced cell surface expression as compared to wild-type. Thus, these results provide 
evidence that key mutations in the active site (S624V) and in the TM domain (G10L) 
that reduce exopeptidase activity also reduce cell surface localization when 
overexpressed in HEK293 cells. Interestingly, these results are also consistent with a 
role for the FAP TM domain in regulating homodimerization, disruption of which 
diminishes exopeptidase activity, versus active-site mutations (S624V) that directly 
eliminate proteolytic activity. 
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Figure 2.7: Cell surface localization is reduced for interfacial, transmembrane 
mutation G10L. Surface proteins were labeled using biotinylation and separated from 
the cell cytosol using streptavidin resin. Comparing surface versus intracellular levels of 
FAP, mutant G10L and S624V both show reduced surface expression and increased 
intracellular accumulation relative to wild-type FAP. 
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2.4:   Discussion 
Previous studies investigating the dimerization of prolyl endopeptidases have 
suggested a role for both the ectodoman and TM domain in terms of homodimerization 
and proteolytic activity (6, 10). In particular, a previous study of DPPIV TM domain 
identified a small-X3-small motif (GLxGA), with mutations to the leucine 11 and 
alanine 14 having a disruptive effect on dimerization in cell membranes (11). The 
small-X3-small motif, first described for Glycophorin A (GpA), is one in which small 
residues are placed along one face of the -helix providing a shallow, weakly polar 
groove that complement the surface of an adjacent helix and allow the helices to pack 
together closely (12-15). In this particular study, the non-conservative proline mutation 
(i.e., L11P and A14P), rather than leucine or alanine mutations, were the only mutations 
capable of disruptive homodimerization; proline strongly destabilizes the hydrogen 
bonding network of the -helical backbone structure and can induce kinking of -
helices, so that the observed, proline-specific effect on disruption of DPPIV 
dimerization may also be a consequence of destabilizing helical folding and stability 
versus packing in the homodimer interface (11, 16). Our work indicates specificity in 
terms of TM-mediated homodimerization for FAP via the extended, small-X3-small 
motif (G10-X3-S14-X3-A18; Figure 1), as leucine mutations to key residues in the TM 
interface disrupt dimerization; unlike proline, leucine has a strong propensity to 
promote -helix formation, and leucine mutations to replace small and polar residues 
within the small-X3-small interface are disruptive to TM homodimerization, whereas 
serine-to-glycine mutations that retain the TM dimer small-X3-small packing interface 
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have no effect on dimerization (17). Thus, our work is most consistent with a model in 
which the FAP TM domain dimer packs via a conserved, small-X3-small motif. 
For FAP, there is relatively little known regarding what, if any, specificity role 
the TM domain plays in regulation of proteolytic activity. Previous studies have focused 
on soluble, engineered ectodomain fragments expressed from mammalian, insect or 
yeast cells; in both cases, the ectodomains were capable of homodimerization (4, 18, 
19). Our results for exopeptidase activity indicate that in fact, G10L, which is important 
in TM domain homodimerization, also markedly decreases exopeptidase activity when 
overexpressed in transfected HEK293 cells (Figure 3D); in the current study, cells were 
washed prior to analysis to remove any competing effects on activity from soluble, 
ectodomain FAP shed from the cell surface. For DPPIV, mutations that disrupt TM 
domain homodimer formation also reduce exopeptidase activity in the full-length 
enzyme, consistent with a role for TM-mediated dimerization regulating exopeptidase 
activity (11); in the current study with FAP, a similar correlation is observed, although 
unlike DPPIV, a specific TM interface (G10-X3-S14-X3-A18) is responsible for 
homodimer formation, which in turn is also important for exopeptidase activity. 
As FAP is a type II integral membrane protein, in which the TM domain also 
acts as a signal peptide to direct trafficking to the cell surface, it is interesting to 
consider the effects of mutations in the TM domain that alter dimerization and activity 
versus subcellular localization. For transmembrane, type II serine proteases, trafficking 
and recycling have been shown to depend largely on N-terminal, cytoplasmic residues 
rather than transmembrane residues (20). For FAP, we find that the specific TM 
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mutation G10L, which reduces exopeptidase activity and TM domain dimerization, has 
a significantly higher ratio of intracellular versus cell surface FAP, as does mutant 
S624V, which eliminates the catalytic serine residue in the enzyme active site. 
Previously, a rare FAP variant (S363L) was found to exhibit reduced conformation-
specific antibody binding and increased ER retention; the mutation occurs in the 
conserved, -propeller domain of the ECD, which was thought to destabilize the fold of 
FAP, yet high overall levels of FAP expression and intracellular accumulation persisted 
(21). Give that G10L occurs in the TM domain rather than in an extracellular region of 
extended secondary- or tertiary structure, our results are most consistent with a role for 
reduced activity and trafficking due to loss of dimer formation rather than 
destabilization of ECD folding.  
 
2.5:   Conclusions  
In summary, we show that FAP homodimerization is dependent on a specific 
transmembrane interface, and regulates exopetidase activity and subcellular 
localization. While previous studies have demonstrated that soluble forms of FAP are 
dimeric, we provide evidence that the TM domain of FAP, particularly a conserved 
small-X3-small motif, is important for dimerization. Given the crticial role of FAP as a 
key source of collagenase activity in tumor cells, and its endogenous overexpression on 
the surface of tumor cells in an active form, there is increasing interest in therapeutics 
targeting FAP (22). Thus, our results provide insight into how membrane-bound 
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dimerization regulates FAP activity, as well as suggests novel approaches to inhibiting 
FAP activity. 
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Chapter 3 
 
The Hydrophobic and Aromatic Residues in FAP 
Ectodomain interface affect Exopeptidase activity 
Fibroblast activation domain (FAP) is a well-known potential target with unique 
potential for addressing the challenges of cancer drug development and delivery. It is a 
transmembrane protein that has heightened expression in the tumor mass in lung, 
colorectal, and breast carcinomas. The crystal structure of FAP showed that 
extracellular domain is homodimeric. Dimerization of FAP is required for enzymatic 
activity. However, the effective residues involving in activity relating with dimerization 
or protein folding remain unclear. The hydrophobic residues buried in the homodimer 
interface assist to stabilize dimer formation as found in DDPIV. Here, we focus on the 
hydrophobic and aromatic residues (W728, F724 and Y239) buried in homodimeric 
interface of FAP ectodomain. Compared to the off-interface A657V mutant, W728A, 
F724A and Y239A FAP constructs exhibit decreased exopeptidase activity (74%, 75% 
and 59% less exopeptidase activity than wild-type, respectively), whereas no decrease 
in exopeptidase activity occurs for the A657V mutant. The mutations in hydrophobic 
and aromatic residues (W728, F724 and Y239) buried in homodimer interface of FAP 
ectodomain also impair trafficking to the cell surface when they are overexpressed in 
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HEK293 cells. Collectively, my results indicate that mutants W728, F724 and Y239 
affect both enzymatic activity as well as trafficking. 
3.1: Introduction  
Seprase or Fibroblast Activation Protein (FAP) is a type II integral membrane 
serine peptidase. It is a cell surface glycoprotein that contains an extracellular domain 
comprised of a catalytic domain in characteristic of a serine protease, a transmembrane 
domain (TM domain), and a short cytoplasmic tail (1). FAP is along with dipeptidyle 
peptidase protein family the same as DPPIV that have mostly 50% identity in amino 
acid sequence with FAP (2). Moreover, a crystal structure of FAP exhibits a DPPIV like 
fold and form to be homodimeric (3). FAP and DDPIV are homodimeric enzymes and 
their dimerizations are required for enzyme activity (4, 5). A soluble, homodimeric 
form of FAP that having been also identified as the soluble form of Antiplasmin 
Cleaving Enzyme (APCE) is shed from the plasma membrane and it is required for 
gelatinase and dipeptidyl peptidase activity (6). Previous work  found that homodimer 
formation is required for FAP activity using gelatin zymography and size exclusion 
chromatography (6). These studies showed that the homodimeric, soluble ectodomain 
form of FAP cleaves gelatin, the fluorogenic exopeptidase substrate Ala-Pro-7-amino-3-
trifluoromethylcoumarine (AFC) and the fluorogenic exopeptidase substrate, Z-Gly-
Pro-7-Amino-4-Methylcoumarin (AMC). However, no such activities against any of 
these substrates in a monomeric form (6). It indicates that dimerization is necessary for 
enzymatic function of FAP and the ectodomain of FAP might be a part to drive the FAP 
dimer formation. However, the direct link between residues relating to stability of FAP 
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dimer and its activity has not been established. According to the FAP crystal structure, 
the hydrophobic and aromatic residues (Phe724, Trp728 and Try 239) buried in the 
dimer interface might provide evidence regarding the relationship between dimer 
interface and the exopeptidase activity of FAP. Mutation in another hydrophobic 
residue surrounding the S1 and S2 Pockets as FAP
A657
 (3) is off-interface homodimer of 
FAP ectodomain. As mentioned above, the effect of mutation to these hydrophobic and 
aromatic residues in dimer interface of the FAP ectodomain relating with enzyme 
activity, comparing to the residues off-interface homodimer, is still unknown. 
Here, we mutated the bulky hydrophobic residues (Phe724, Trp728 and Try 
239) buried in the dimer interface to be the smallest hydrophobic residue as alanine. 
This site-directed mutagenesis of these residues in the dimer interface of FAP 
ectodomain might provide evidence regarding the relationship between hydrophobic 
and aromatic residues in FAP homodimer interface and the FAP exopeptidase activity. 
3.2: Materials and Methods 
3.2.1: Materials 
The Human Embryonic Kidney (HEK) 293T/17 cells were purchased from 
American Type Culture Collection (ATCC). DMEM was supplied from Mediatech, Inc 
(Corning Subsidiary). Fetal bovine serum was from GE healthcare life sciences. 
Lipofectamine 2000 was obtained from Life Technologies. All restriction enzymes were 
purchased from New England BioLabs. QuickChangeII site directed Mutagenesis kit 
for site-directed mutagenesis was from Agilent technologies. H- Ala-Pro –AFC for 
enzyme activity test was obtained from Anaspec. Inc. EZ-Link™Sulfo-NHS-Biotin, and 
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Streptavidin Magnetic Beads were purchased from Themo scientific. The Purified 
HA.11 Clone 16B12 Monoclonal Antibody was purchase from BioLegend.  Biomax 
Light Film was from Carestream Health, Inc. All chemicals for preparing all buffers 
were obtained from Alfa Aesar, Sigma-Aldrich, J.T Baker Chemical, CalBiochem and 
Amresco. 
3.2.2: Methods 
3.2.2.1: Subcloning FAP full-length gene and Site-directed mutagenesis 
The full-length FAP was amplified with the forward primer containing SacI (5’-
GAGCTCATGAAGACTTGGGTAAAAATCGTATT-3’) and the reward primer containing 
KpnI and HA tag (5’- GGTACCTTAGGCGTAGTCGGGCACGTCGTAGGGGTAGTCTGA 
CAAAGAGAAACA -3’). Then, it was cloned into mGFP-N2 plasmid. The in-frame FAP 
sequences in the plasmid were confirmed by DNA sequencing (Genewiz). The significant 
mutation points in ectodomain were predicted by using PyMOL program. Site-directed mutants 
in ectodomain domain were generated following QuickChangeII site directed Mutagenesis kit’s 
instruction.    
3.2.2.2: Cell transfection, expression and dipeptidyl peptidase assay 
Each plasmid containing FAP wild-type and FAP ectodomain mutants was 
transient transfected in HEK293T cells by using Lipofectamine2000, according to the 
manufacturer’s instructions. Each chemical-transfection was carried out on a 6-well 
plate with 4 ug of plasmid. As determined by fluorescence microscope from a HEK-
mock (mGFP-N2), transfection showed around 80-90 % efficiency. Cells were 
collected after it was incubated in 37 
o
C, 5% CO2 incubator for 48 hours. Then cells 
were washed with 1X PBS and lyzed with 1X RIPA buffer (20 mM Tris pH 7.5, 150 
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mM Nacl 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1 mM -glycerolphosphate, 2.5 mM 
Sodium pyrophosphate) without serine protease inhibitors on ice for 15 minutes. The 
cell lysate was incubated in substrates H-Ala-Pro-AFC (500 uM) for 5 minutes. 
Hydrolysis product was monitored as fluorescence intensity with times at excitation and 
emission wavelengths of 400 and 510 nm for 1 hour at 37 C. Release of the free 7-
amino-3-trifluoromethylcoumarine (AFC) group after dipeptide cleavage following the 
Pro residue is measured through fluorescence detection using the 395 nm excitation/530 
nm emission filter set in a M200 Infinity plate reader (Tecan). Enzyme kinetic 
parameters (Michaelis-Menten Km values) can be calculated from this assay in terms of 
the increase in fluorescence activity (7) The change of activity between wild-type FAP 
and mutants were compared in 1 hour in the bar graph.  
3.2.2.3: Immunoblotting Assay  
Immunoblotting of Full-length FAP wild type and FAP ectodomain mutant 
expression in HEK T cells, cells were collected after transfection for 48 hours. The cell 
lysate was mixed with 5X Lammeli sample buffer containing -mecaptoethanol and 
heated for 10 minutes. Samples were loaded into 8% SDS- acrylamide gel and run in 
SDS running buffer, then transferred to a nitrocellulose membrane for 90 minutes. After 
the transferred membrane was blocked with 5% milk in TBST for 1 hour at room 
temperature, it was incubated with 1:1,000 dilution of anti HA monoclonal antibody in 
incubator shaker at 4C overnight and 1:1,000 of the secondary mouse IgG antibody at 
room temperature for 1 hour. After incubating the membrane with a chemiluminescent 
substrate (GE) in dark for 5 minutes, it was exposed with an autoradiography flim 
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(Carestream Kodak BioMax light film) and developed using film processor for X- ray 
machine (SRX-101A, Konic Minolta).  
3.2.2.4: Biotinylation and immunoprecipitation procedures  
The transfected cells both wild-type FAP and mutants was collected and washed 
with 1XPBS pH 8.0 for three times before they were resuspended at a concentration of 
~1 × 10
6
 cells/mL in PBS (pH 8.0). EZ-Link™Sulfo-NHS-Biotin was used as a reagent 
to link with a primary amino groups (-NH2) of FAP transmembrane protein. The 
protocol was followed to the manufacturer’s instructions. After the cells were incubated 
with Sulfo-NHS-Biotin for 30 minutes at room temperature, excess biotin reagent and 
byproducts were quenched and removed with 1X PBS plus 100mM glycine. Pre-washed 
streptavidin magnetic beads in the final concentration of 0.5 mg/sample were added in 
the Sulfo-NHS-Biotin linked cells that were resuspended with 300 uL PBST (pH 7.5). 
After incubating for 1 hour at room temperature, the beads were wash with IP wash 
buffer (PBST, pH7.5) for three times and then, 60 µl of 5X SDS-PAGE reducing 
sample buffer containing -mercaptoethanol was added to the tube. Each sample was 
heated at 100˚C in a heating block for 5 minutes. The supernatant containing FAP 
transmembrane protein was collected and magnetically separate from beads. The 
samples were run in 8% non-denaturing gel and analyzed with western blotting against 
anti HA monoclonal antibody. 
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3.3: Results 
3.3.1: Critical residues in dimer interface of the FAP ectodomain are identified 
The crystal structure of FAP (PDB accession code IZ68) has confirmed that the 
FAP ectodomain exists as a homodimer. This dimerization might be necessary for 
enzymatic function (3). The recombinant FAP, expressed in yeast cells and secreted in 
the supernatant, exhibits enzyme activity in a dimer form, but not in a monomeric form 
(6). The dimer interface of the FAP ectodomain might be involved in the homodimer 
formation and activity of soluble FAP. PyMoL is a molecular graphics system with an 
embedded Python interpreter designed for real-time visualization and rapid generation 
of high-quality molecular graphics images and animations (8). We used this tool to 
predict the critical residues that are important for homodimerization and activity within 
the FAP dimer interface. As shown in Figure 3.1, we found residues with a bulky 
hydrophobic and aromatic side chain buried in the FAP dimer interface. These residues 
could be crucial for FAP activity through stabilization of a dimer formation. The 
hydrophobic and aromatic residues (Phe724, Tyr 239 and Trp728) which are predicted 
as the buried residues in FAP homodimeric interface were mutated to be an alanine 
residue, comparing with the off-interface residue such as Ala 567 that is involved with 
substrate affinity and promoted Z-Gly-Pro-AMC endopeptidase cleavage (3). 
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Figure 3.1: Model of the FAP Dimer. FAP monomers are shown in blue and green. 
The red box shows the dimer interface. The hydrophobic residues Phe724, Trp728 and 
Tyr 239 are buried within the dimer interface. 
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 3.3.2: FAP ectodomain mutants disrupts FAP exopeptidase activity 
The FAP wild-type and FAP ectodomain mutants were sub-cloned into mGFPN2 
that is the plasmid containing GFP signal. However, we placed a stop codon in the end 
of FAP full-length gene so no GFP was expressed in our samples. Only a negative 
control that is the mGFPN2 without the FAP gene showed GFP signal in the 
fluorescence microscope. Expression from the negative control showed that a 
transfection efficiency of this experiment was around 80-90%. Both FAP wild-type and 
FAP ectodomain mutants were expressed in HEK293T cells, a human cell line 
containing the addition of the SV40 large T antigen. This cell line can increase vector 
production and improve a high yield of protein expression (9). The expression level of 
both the FAP-wild-type and FAP ectodomain mutants are not significantly different 
after their expression are compared with the expression of housekeeping protein such as 
tubulin (Figure 3.2). Therefore, the cell lysate from both FAP-wild-type and FAP 
ectodomain mutants were used to determine for dipeptidyl Peptidase activity by using 
the same amount of the protein lysate. 25 uL of the cell lysate in each sample was used 
for exopeptidase activity test against H- Ala-Pro –AFC and the results were interpreted 
in the term of fluorescence activity for 1 hour at 37 C. The results were presenting in 
the normalized fluorescence intensity divided by protein lysate concentration of each 
sample. The bar graph in figure 3.3 shows that dipeptidyl peptidase activities of 
W728A, F724A and Y239A constructs were diminished 74%, 75% and 59%, 
respectively from WT. Whereas, dipeptidyl peptidase activity of A657V construct are 
not different significantly from WT. The mutation in serine residue as S624V, a proton 
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donor in an active site, also completely reduces dipeptidyl peptidase activity. The 
results indicate that the hydrophobic and aromatic residues in dimer interface of the 
FAP ectodomain (W728, F724, and Y239) are important for FAP exopeptidase activity, 
whereas, another hydrophobic residue in off-homodimeric interface of FAP ectodomain 
such as Ala 567 has not shown an effect to FAP exopeptidase activity.   
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Figure 3.2: Expression of the full-length FAP WT and hydrophobic residue 
mutants in HEK293T cells. Western blotting was done using an anti-HA monoclonal 
antibody. Full-length FAP WT and mutant FAP constructs were transiently expressed in 
HEK293T cells. The expected sized of the FAP monomer is around 97 kDa. An anti-
tubulin blot confirms the same amount of protein loading of each construct. 
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Figure 3.3: Exopeptidase activity for WT and mutant FAP constructs. Values 
represent fluorescence intensity normalized to total protein concentration, with higher 
fluorescence intensities indicating greater FAP activity against H-Ala-Pro-AFC. 
HEK293T cells were transiently transfected with WT or ectodomain mutant FAP and 
allowed to grow for 48 hours. The negative control is lysate from empty mGFP-N2 
transfected cells. 
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3.3.3: FAP ectodomain mutants affect protein trafficking into HEK293 cell 
membrane. 
The expression levels of the membrane protein between FAP wild-type and FAP 
ectodomain mutants were determined by using the immunoprecipretation assay. EZ-
Link NHS-Biotin will bind with primary amines of protein surfaces and then, the excess 
NHS was quenched and removed with glycine. The streptavidin magnetic beads were 
pulling out only the membrane protein from the cell. Therefore, the supernatant eluated 
from beads is only FAP tramsmembrane protein. This procedure was done with the 
1*10
6
 suspended cells in 1X PBS pH 8 of both FAP wild-type and FAP ectodomain 
mutants. The western blotting against HA-monoclonal antibody as in Figure 3 showed 
that, comparing with the wild-type, there is decrease of the expression level of the 
membrane protein in the mutants. Most expression of the mutants remained in cytosol. 
The results suggest that mutations in the homodimeric interface of the FAP ectodomain 
(W728A, F724A and Y239A) affect protein localization into cell membrane as well.     
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Figure 3.4: Localization in the cell membrane of FAP WT and mutants. They are 
determined via biotin-labeling and immunoprecipitation of FAP proteins expressed in 
HEK293T cells. The western blot against the FAP HA-tag shows that FAP ectodomain 
mutants exhibit a reduced level of expression in the cell membrane and mostly remain 
in the cytosol.   
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3.4 : Discussion 
In general, proteins will fold with hydrophobic residues, away from water. FAP 
is a type II transmembrane protein that has an ectodomain facing in extracellular region 
and form as a dimer with another subunit (3). From the crystal structure, the 
hydrophobic and aromatic residues; W728, F724 and Y239 are found in FAP 
homodimer interface buried away from water environment. These residues were 
predicted as residues required for enzyme dimerization and activity. The mutations in 
theses predicted residues disrupt 74%, 75% and 59% of enzyme activity relative to WT 
in W728A, F724A and Y239A, respectively. The results are consistent with the study in 
the ectodomain of DPPIV. DPPIV also requires dimerization for its activity (4, 5, 10, 
11). The mutations either F713A or W734A, a residue in the homodimer interaface of 
DPPIV, destabilize DPPIV dimer formation. Without DPPIV TM domain, the 
mutations in these hydrophobic residues completely disrupt DPPIV dimerization and 
had 5% enzymaitic activity of WT against Gly-Pro-pNA (12). The results indicate that 
the hydrophobic residues buried in homodimeric interaface of DPPIV are important for 
dimer stability and activity.  
Chien et al, 2006 also used analytical ultracentrifugation (AUC) to measure 
sedimentation velocity and sedimentation equilibrium of DPP-IV protein wild-type and 
mutants and showed that single-site mutations at F713, W734, or Y735 of DPP-IV 
effect to the quaternary structure of DPP-IV (5). The decreases of more than 50% 
exopeptidase activity relation to FAP WT of the mutants (W728A, F724A and Y239A) 
show that hydrophobic and aromatic residues buried in homodimeric interface of 
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ectodomain require for FAP exopeptidase activity. It can be possible that mutations in 
the hydrophobic residues buried in FAP homodimer interface might cause a 
conformational change of FAP that have an effect to enzymatic activity.  
The mutants in the hydrophobic and aromatic residues of FAP ectodomain result 
to reduce FAP expression in cell membrane. The results might be involve to a complex 
network of cellular quality control pathways in eukaryotic cells to recognize misfolding 
transmembrane proteins and facilitate their refolding or degradation (13-15). 
Previously, the unfolded ATF6, a type II transmembrane glycoprotein, was degraded 
through ER-associated degradation (ERAD) pathway (16). Our results are consistent 
with the result of the experiment in the cystic fibrosis transmembrane conductance 
regulator (CFTR). Deletion of the hydrophobic residue (F508CFTR) causes losing of 
the protein expression in the plasma membrane (17). Mutation in this hydrophobic 
residue of CFTR leads to unfolding and subsequent ubiquitination, internalization, and 
lysomal degradation. Comparing with wild-type CFTR, F508CFTR has the folding 
defect and was retained in the ER (17-19). It suggested that the hydrophobic residue 
serves as the key residue for protein folding and relates to degradation and localization 
of membrane protein. Therefore, our results are most consistent with a role for reduced 
protein expression in plasma membrane due to a role of hydrophobic residues involving 
in FAP folding and dimerization. 
3.5 : Conclusions 
In summary, we show that the hydrophobic and aromatic residues in the FAP 
ectodomain interface are involved in FAP activity and regulate protein expression in 
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cell membrane. The residues (W728, F724 and Y239) in FAP ectodomain interface 
might be important for protein folding. Then, the mutation in these residues leads FAP 
to be the nonfunctional or dysfunctional protein. Thus, the results in this paper provide 
insight into how hydrophobic and aromatic residues buried in homodimeric interface of 
FAP ectodomain regulates FAP exopeptidase activity and localization. 
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Chapter 4 
 
Designed substrate specificity for FAP selective 
targeting 
4.1: Introduction  
Fibroblast Activation Protein (FAP) or Seprase is a type II  cell surface glycoprotein 
that contains an extracellular domain comprised of a catalytic domain characteristic of serine 
proteases, a transmembrane domain (TM domain), and a short cytoplasmic tail (1, 2). FAP is 
grouped in the subfamily S9b of the peptidase family S9 (prolyl oligopeptidaes family) and clan 
SC that is known to cleave prolyl peptide (Pro-Xaa) bonds (3). The proteases in this family 
include FAP, and dipeptidyl peptidase IV,8 and 9 ( DPPIV, DPP8 and DPP9) and have an 
ability to hydrolyze the prolyl bond two residues from the N-terminal (4-7). The ability to 
cleave a post-proline bond is a distinguishing characteristic of these proteases (8). Within this 
family of proteases, FAP is unique in that it can cleave gelatin and type I collagen, but cannot 
able to cleave human fibronectin, laminin, or collagen IV (6). This unique specificity for type I 
collagen as well as denatured collagen is not exhibited by other serine proteases in the same 
family, such as DPP-IV and the related type II transmembrane propyl serine peptidases. 
Therefore, FAP is a proline-specific protease that exhibits endopeptidase activity as well as 
exopeptidase activity (9, 10).  
FAP expression is restricted to sites of tissue remodeling and activated stroma. It is not 
expressed in normal adult tissue (11). FAP degrades the extracellular matrix (ECM) in 
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processes involving healing, malignant tumor growth and chronic inflammation. The gelatinase 
activity of FAP may play an important role in ECM degradation, and FAP may be a biomarker 
for certain cancers because it is associated with fibrosis, cell migration and apoptosis. There are 
numerous recent studies reviewing the role of FAP in human diseases (12-15), however an 
understanding of FAP’s substrate specificity is still limited. Design of a specific FAP substrate 
is a crucial step in gaining insights for understanding the precise mechanisms and functions of 
FAP in biology and disease.          
The endopeptidase activity of FAP distinguishes this protease from others. Here, we 
have designed a FAP-selective peptide (FAPS) with an end-goal of using the peptide as a 
protease-responsive peptide to examine FAP’s endopeptidase activity. This peptide will serve as 
a model to test delivery systems for targeting cancer cells and accessing the tumor 
microenvironment (TME). These goals will provide the insight to guide strategies to design an 
efficient drug delivery system for anti-cancer therapies based on FAP activity. 
4.2: Materials and Methods 
4.2.1: Materials 
The oligonucleotide primers were ordered from Integrated DNA Technologies, 
Inc (IDT). All restriction enzymes for sub-cloning were purchased from New England 
BioLabs. The backbone plasmids were provided by Invitrogen. HisPur Ni-NTA Resin 
for immobilized metal ion affinity chromatography (IMAC) was purchased from GE-
Healthcare. The Human Embryonic Kidney (HEK) 293T/17 cells for FAP and DPP-IV 
transient expression were purchased from American Type Culture Collection (ATCC). 
DMEM was supplied by Mediatech, Inc (Corning Subsidiary). Fetal bovine serum was 
from GE Healthcare Life Sciences. Lipofectamine 2000 was obtained from Life 
Technologies. The Purified HA.11 Clone 16B12 Monoclonal Antibody was purchase 
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from BioLegend. Pierce ECL-2 western blotting substrate was obtained from Thermo 
Scientific. MMP-9 (catalytic domain) (human) (recombinant, E. coli) was purchased 
from Enzo Life Sciences, Inc. IPTG was from GoldBio. Chemicals for preparing 
buffers and media were obtained from Alfa Aesar, Sigma-Aldrich, J.T Baker 
Chemicals, CalBiochem or Amresco. 
4.2.2: Methods 
4.2.2.1: Designed of a FAP-Selective Peptide (FAPS) and Cloning of the MBP-
FAP-Selective Peptide for Protein Expression 
The repeated sequences DRGETGPA and SGPKTSGPKT were used for the 
FAPS. These amino acid sequences are the FAP consensus sequences within the 
cleavage site of human collagenI (10, 16). The GeneDesign program was used to 
convert this specific amino acid sequences to random nucleotide sequences. Then 
overlapping oligonucleotides were synthesized and used as the PCR template (Table 
4.1). All restriction enzymes were purchased from New England BioLabs. Overlapping 
oligonucleotide primers for the FAPS synthesis were designed using the Oligoperfect
TM
 
program (Invitrogen). The full-length FAPS gene fragments of both constructs contain 
the BamHI and XhoI restriction sites because of using FAPS forward primer containing 
BamHI and FAPS reverse primer containing XhoI. The PCR was performed in a total 
volume of 40 µL, with the mixture containing 20 µM of each primer, 1X GoTaq Green 
Master Mix (New England BioLabs) and 2 µL of each overlapping oligonucleotide. 
Amplification cycles were: one 5 minute cycle at 95
o
C, 30 cycles of 95
o
C for 30 
seconds, 55
o
C for 1 minute and 72
o
C for 2 minutes, then 10 minutes at 72
o
C. The PCR 
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fragment was digested for one hour in the reaction containing with BamHI and XhoI 
and then run on a Tris-borate-EDTA (TBE) gel. The expected fragments were gel-
purified following Li et al.’s instruction (17). The digested PCR product was ligated 
into pET42-MBP and pET28 plasmids donated by Logan MacDonald. For propagation 
of plasmids with the FAPS genes, we transformed these plasmids into DH5α competent 
cells using a 1.8 kV pulse electroporation. Sequencing results were confirmed by 
GeneWiz. The plasmids were transformed into BL-21 competent cells for protein 
expression. Kanamycin was used to select for cells with the plasmid of insert.  
4.2.2.2: Expression and Identification of The  FAP-Selective Peptide Recombinants 
in E.coli  
The transformants were grown in 150 mL LB medium at 18 
o
C and 200 RPM 
until the OD600 reached five to six. Then FAPS expression in the cells was induced 
with 1 mM IPTG and the culture was further incubated under the above condition for 
16-18 hours. The cell pellet was collected by centrifugation and lysed by freezing and 
thawing in lysis buffer [50 mM Hepes pH 7.4, 200 mM NaCl, 10 mM imidazole, 1 
mg/mL lysozyme and 1 mM PMSF]. The soluble proteins were observed on a SDS-
PAGE gel and both FAPS constructs were detected by using western blotting.  
4.2.2.3: Immobilized Metal Ion Affinity Chromatography (IMAC) 
The purification of the repeated DRGETGPA and SGPKTSGPKT proteins 
occurred via the following IMAC purification method (18). The HisPur Ni-NTA Resin 
was equilibrated with IMAC wash 1 buffer (20 mM HEPES, 500 mM NaCl, 10% 
glycerol, 10 mM imidazole and 0.5 mM TCEP, pH 7.5) or SEC buffer (20 mM HEPES, 
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300 mM NaCl, 10% glycerol and 0.5 mM TCEP pH 7.5). The soluble FAPS proteins in 
lysis buffer were loaded in the gravity column. The IMAC washes 1 and 2 (20 mM 
HEPES, 500 mM NaCl, 10% glycerol, 25 mM imidazole and 0.5 mM TCEP, pH 7.5) 
were applied to the column sequentially to remove unwanted proteins. The FAPS were 
eluted from the column with an IMAC elution buffer (20 mM HEPES, 500 mM NaCl, 
10% glycerol and 0.5 mM TCEP, pH 7.5) containing 300 mM, 400 mM, or 500 mM 
imidazole. Successful purification was confirmed by SDS-PAGE. The purified FAPS 
were dialyzed in SnakeSkin®Pleated Dialysis Tubing (Thermo Scientific) against 1X 
PBS (0.137M Sodium Chloride, 0.0027M Potassium Chloride, and 0.0119M 
Phosphates) for 16-18 hours. For the FAPS inserted in a pET42-MBP plasmid, the 
purified protein was cut with thrombin before digestion tests of the peptides with FAP. 
The MBP-FAPS protein was dissolved in reaction buffer (50 mM Tris pH7.5, 100 mM 
NaCl and 1 mM EDTA) at a final concentration of 100 g/mL and 5 ug/mL of FAP was 
added. The reaction was incubated overnight.  
Protein concentrations were determined using a Micro BCA
TM
 protein assay kit 
(Thermo Scientific). The protein standard (BSA) was diluted in 50 mM imidazole lysis 
buffer to concentrations of 5.0, 10.0, 20.0, 40.0, 100.00, and 200.00 µg/mL. A volume 
of 150 µL of the protein standard and 150 µL of the kit’s instant reagent were mixed 
and placed into a microtiter plate. A mixture with 50 mM imidazole lysis buffer without 
protein was used as a blank. The reactions were incubated at 37
o
C for 2 hours. The 
absorbance at 560 nm was measured for the protein standard and samples using an 
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Infinite F200 (TECAN, USA). The concentrations of protein samples were calculated 
by referring to the protein standard curve.  
4.2.2.4:  Cell Transfections and Expression FAP and DPP-IV in HEK293T Cells 
Each mGFP-N2 plasmid containing FAP wild-type (WT), FAP S624V or DPP-
IV was transiently transfected in HEK293T cells by using Lipofectamine2000, 
according to the manufacturer’s instructions. Each chemical-transfection was carried 
out in a sigle well of a 6-well plate with 4 g of plasmid. As determined by fluorescence 
microscope from a HEK293T cells transfected with empty mGFP-N2, transfections 
were 80-90 % efficient. Cells were collected after incubation at 37oC with 5% CO2 for 
48 hours. Then cells were washed with 1X PBS and lysed with 1X RIPA buffer (20 mM 
Tris pH7.5, 150 mM NaCl 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1 mM -
glycerolphosphate, 2.5 mM sodium pyrophosphate) without serine protease inhibitors 
on ice for 15 mins. The cell lysate was collected for an activity test. 
4.2.2.5: The Repeated FAP-Selective Peptide Digestion 
 The purified FAPS in 1X PBS after dialysis were diluted to 0.2 g/mL for the 
digestion test. Lysates from HEK293T cells expressing FAP WT, FAP S624V, or DPP-
IV were added to the reactions containing the repeated DRGETGPA or SGPKTSGPKT 
peptides. The reactions were incubated for 24 hours at 37 
o
C. The digestion of the 
repeated DRGETGPA or SGPKTSGPKT peptides was analyzed by western blotting 
using an anti-HA monoclonal antibody. For determination of proteolytic synergy 
between MMP-9 and FAP-WT for degrading the repeated DRGETGPA or 
SGPKTSGPKT peptides, 1.2 ng of MMP-9 was added to the mixture of the repeated 
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DRGETGPA or SGPKTSGPKT peptides and the cell lysate. The reactions were 
incubated for 24 hours at 37 
o
C.  
4.2.2.6: Immunoblotting Assay 
 The HEK293T cells exppressing FAP WT and DPP-IV were collected 48 hours 
after transfection. The cell lysate was mixed with 5X Laemmeli sample buffer 
containing -mercaptoethanol and heated for 10 minutes. Samples were loaded into 
10% SDS- PAGE gels and run in SDS running buffer. The Xcell IITM Blot Module 
was used to transfer samples from the acrylamide gel onto an AmershamTM 
HybondTM-ECL membrane. The membrane was pre-wet and equilibrated in transfer 
buffer (25 mM Tris, 192 mM glycine, 10% methanol). The transfer was performed at a 
constant amperage of 200 mA at 4
o
C for 1.5 hours. After, the transferred membrane was 
blocked with 5% milk in TBST (10 mM tris-aminomethane hydrochloride pH 7.3, 100 
mM NaCl and 0.1% Polysorbate 20) for 1 hour at room temperature, after which it was 
incubated with 1:1,000 dilution of an anti-HA monoclonal antibody shaking at 4
o
C 
overnight and 1:1,000 of the secondary mouse IgG antibody at room temperature for 1 
hour. After incubating the membrane with the ECL Plus Western Blotting Detection 
System in the dark for 5 minutes, the membrane was exposed with an autoradiography 
film (Carestream Kodak BioMax light film), and the film was developed using a film 
processor for X- ray machine (SRX-101A, Konic Minolta). For immunoblotting for 
determination of the cleavage of the repeated DRGETGPA or SGPKTSGPKT peptides, 
the digested samples were analyzed on a 15% acrylamide gel and run in 1 X MES 
running buffer. The transfer to the membrane was as described above. After blocking 
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with 5% milk in TBST for 1 hour at room temperature, the membrane was incubated 
with 1:1,000 dilution of an anti-HA monoclonal antibody shaking at room temperature 
for 1 hour and 1:1,000 of the secondary mouse IgG antibody at room temperature for 
another  hour. The results were imaged using a Typhon imager.   
4.3: Results 
4.3.1: Expression and purification of the repeated FAP substrates  
A study by Aggarwal et. al. (10) analyzed the frequency of each amino acid 
within the FAP cleavage sites using liquid chromatography/tandem mass spectrometery 
(LC/MS/MS). They showed a complete map of the FAP cleavage sites within the 
recombinant forms of human collagen I-derived gelatin. FAP preferred to cleave after 
the G-P dipeptide; the consensus sequences can be represented as PPGP and (D/E)-
(R/K)-G-(E/D)-(T/S)-G-P in the collagen cleavage sites. Moreover, FAP also preferred 
an amino acid in the position after the G-P dipeptide within a substrate. The human 
collagen I forms a heterotrimeric polymer made up of repeating sequences containing 
the (GXY)n motif (X is Pro and Y is hydroxyl-Pro) (19). Due to FAP ‘s unique ability to 
cleave gelatin and human collagen I, we therefore designed the repeated substrate 
peptides for FAP based on the human collagen I derived gelatin cleavage sites and 
expressed these peptides in E.coli system. Two different repeated peptide sequences of 
DRGETGPA and SGPKTSGPKT (Figure 4.1A) were generated using PCR. The 
synthesized, overlapping oligomer nucleotides were used as templates to amplify the 
full-length gene of the repeated peptide substrates. All oligonucleotide sequences were 
designed via the GeneDesign website (www.genedesign.org). Two chimeric protein 
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substrates were expressed in an E.coli system and purified with a HisPur Ni-NTA resin 
gravity column. Both repeated peptide substrates contained an HA-tag 
(YPYDVPDYA). Therefore, protein bands blotting positive upon treatment with an 
HA-Tag (6E2) mouse monoclonal antibody (HRP-conjugated) indicate expression of 
the expected recombinant substrates. First, we sub-cloned the repeated peptide 
substrates into pET42-MBP and expressed the constructs in BL21 competent E.coli. 
Maltose-binding protein (MBP) fusions have been used as part of a general strategy for 
enhancing expression of proteins in E. coli. Hewitt et al., showed that a chimeric 
expression vector with an N-terminal histidine-tagged MBP results in a high yield of 
soluble protein expressed in an E. coli T7 expression system (20). In our experiment, 
we used a modified pET42 vector (Figure 4.1B) containing an N-terminal histidine-
tagged MBP for E.coli expression. We performed subsequent purification with nickel 
immobilized metal ion affinity chromatography (IMAC). The 50 kDa MBP-
SGPKTSGPKT and 54 kDa of MBP-DRGETGPA protein were detected with an HA-
tag (6E2) mouse monoclonal antibody (HRP-conjugated western blot (Figure 4.1C). 
Due to difficulties cutting and purifying the repeated peptide substrates from MBP, the 
test digestions were performed using the fusion proteins. MBP also contains G-P sites 
within the protein sequence, and further processing is needed to test specificity of the 
repeated FAPS. 
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Table 4.1 Synthesized oligonucleotides for FAP substrate design 
 
** DR is strands DRGETGPA and SP for SGPKTSGPKT 
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Figure 4.1: Subcloning of FAPS in pET42 with MBP expression in E.coli. (A) The 
sequences of FAP repeated peptide substrates. These substrates were designed based on 
a map of the FAP cleavage sites within human collagen I derived gelatin. (B) Plasmid 
map of the MBP – FAP peptide substrate construct, with inserts between BamHI and 
XhoI restriction enzyme sites. This expression fuses FAP peptides to His-MBP for 
overexpression in E.coli and purification using IMAC. (C) Western blotting with a HA-
tag (6E2) mouse monoclonal antibody (HRP-conjugated) of FAP substrates. Expected 
molecular weights are 50 kDa for SGPKTSGPKT and 54 kDa for DRETGPA in 
Lane#1 and Lane# 2, respectively. 
(A) 
(B) 
(C) 
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4.3.2:  Re-subcloning of the repeated DRGETGPA and SGPKTSGPKT into 
pET28 
Two different repeated peptide sequences of DRGETGPA and SGPKTSGPKT 
were subcloned in pET28 (Figure 4.2A and B) and expressed in BL21 E.coli. The 
expected protein expression size of the repeated peptides DRGETGPA and 
SGPKTSGPKT are 8 and 6.9 kDa, respectively.However, bands at 14 kDa for 
SGPKTSGPKT and 16 kDa for DRGETGPA were detected using an HA-tag (6E2) 
mouse monoclonal antibody (HRP-conjugated) in a western blot (Figure 4.2C), 
suggesting the two repeated peptides, DRGETGPA and SGPKTSGPKT, exist in dimer 
form. These repeated peptides were purified and dissolved in 1X PBS. We used these 
peptides as a substrate for subsequence FAP specific test.  
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Figure 4.2: Subcloning of FAPS in pET28 and Protein expression in E.coli.  (A) 
The sequences of FAP repeated peptide substrates. These substrates were designed 
based on a map of the FAP cleavage sites within human collagen I derived gelatin. (B) 
FAPS were inserts between BamHI and XhoI restriction enzyme sites in pET28 without 
an MBP fusion. (C) Western blotting with an HA- mouse monoclonal antibody 
illustrated bands at molecular weight of 16 kDa for DRETGPA and 14 kDa for 
SGPKTSGPKT in Lane#1 and Lane# 2, respectively. The proteins are expressed in a 
dimer form. 
(A) 
(C) 
(B) 
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4.3.3: Cleavage of the repeated DRGETGPA and SGPKTSGPKT 
 The repeated peptides DRGETGPA and SGPKTSGPKT in the total 
concentration of 2.4 g were used as substrates in each sample. 25 L or 50 L of cell 
lysate of FAP, DPPIV and FAP S624V were added in the substrate and the reactions 
were incubated at 37 
o
C for 24 hours. No digestion occurred with the repeated peptide 
DRGETGPA (Figure 4.3A), whereas FAP digested the repeated peptide 
SGPKTSGPKT, as indicated by decrease in intensity of FAP-digested SGPKTSGPKT 
bands relative to the mock control (cell transfected with empty mGFP-N2 (Figure 4.3B). 
FAP S626V digestion of the substrate SGPKTSGPKT appeared the same as the 
digestion using the lysate from the mock control (cells in the transfected with empty 
mGFP-N2). Therefore, the decrease in amount of substrate in the reaction that contains 
WT FAP indicates the ability of FAP to cleave SGPKTSGPKT. For collagen I 
digestion, FAP cannot cleave collagen in its native state. It requires matrix 
metalloproteinase (MMP) activity to unwind collagen (16). Here, we also investigated 
the proteolytic synergy between MMP and FAP. The result showed that 50 L of FAP 
lysate and 1.2 ng MMP-9 can completely cleave the SGPKTSGPKT peptides as shown 
in Lane 9 of Figure 4.4. However,even addition of MMP to FAP fails to digest 
DRGETGPA as shown in Lanes 1-5, Figure 4.4. 
 To confirm that the complete cleavage shown in Lane 9 of Figure 4.4 is from 
FAP activity, we examined for lysates from cells transfected with mGFP-N2 or FAP 
S624V for proteolytic activity. As shown in Figure 4.5, there was no difference in band 
intensity between the FAP, DPPIV, mGFP-N2 and FAP S624Vdigestion. However, 
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whether the repeated peptides DRGETGPA and SGPKTSGPKT are specific substrates 
for FAP or not is still unclear. Many factors, such as the appropriate reaction conditions 
and the effect of unpurified FAP, may contribute to FAP specificity. More experiments 
are necessary to confirm FAP specificity for our FAPS. 
4.4: Discussion and Future work  
FAP is over-expressed by activated fibroblasts in the stroma of malignant 
epithelial cancers such as breast, lung, colon and ovarian (21).  It plays an important 
role in facilitating cell invasion into the extracellular matrix. In effort to develop drug 
systems targeting cancer cells, we focused on understanding and systhesizing a small 
specific substrate for this cell surface protease that is abundant in the tumor stroma. 
FAP can cleave collagen I that is a main component of the extracellular matrix (ECM). 
However, FAP cannot cleave type I collagen (CN-I) in its native form. MMP-1 unwinds 
the CN fibers, and facilitates FAP-induced degradation (6, 16). To generate cleavable 
peptides based on the human CN-I derived gelatin cleavage site, the repeated peptides 
DRGETGPA and SGPKTSGPKT were generated using E.coli expression system. We 
expected that these repeated peptides might serve as substrates for investigating FAP 
endopeptidase activity and specificity. These substrates might linked with glucuronan 
gel as part the future project. 
A bacterial -(1,4)-polyglucuronic acid called glucuronan has been isolated and 
identified as the sole exopolysaccharide produced by a bacteria belonging to the 
Rhizobiaceae family. An interesting property of glucuronan is its ability to form a gel in 
the presence of monovalent, divalent, or trivalent cations, depending on ionic strength 
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and  polymer concentration (22). The glucuronan gel has biodregradable and 
biocompatible properties (23), therefore this gel might be potentially useful in many 
applications such as agronomy, cosmetics and therapeutics. 
FAP purification  is major problem in this project that we still try to solve in order to 
determine activity and specificity for FAPS in efforts to develop an in vitro drug 
delivery assay targeting FAP-expressing cells.    
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Figure 4.3: Digestion of the repeated DRGETGPA and SGPKTSGPKT peptide. 
(A) Cleavage of the repeated DRGETGPA peptide. Lanes 1-9 are (1) 25 L 
substrate+mGFP-N2 lysate; (2) substrate without lysate or incubation; (3) substrate 
without lysate incubated in 37
o
C; (4) substrate +25 L FAP WT lysate; (5) substrate 
+25 L DPPIV lysate; (6) substrate +25 L FAP S624 lysate; (7) substrate +50 L FAP 
S624 lysate; (8) substrate +50 L DPPIV lysate;  (9) substrate +50 L FAP WT lysate; 
(-) pET28+FAP WT lysate. (B) Cleavage of the repeated SGPKTSGPKT peptide. 
Lanes 1-9 are (1) substrate +25 L mGFP-N2; (2) substrate without lysate or incubation; 
(3) substrate without lysate incubated in 37
o
C; (4) substrate +25 L FAP WT lysate; (5) 
substrate +25 L DPPIV lysate; (6) substrate + 25 L FAP S624 lysate; (7) substrate + 
50 uL FAP S624 lysate; (8) substrate + 50 uL DPPIV lysate; (9) substrate +50 uL FAP 
WT lysate; (-) pET28+FAP WT lysate. 
(A) 
(B) 
(B) 
(B) 
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Figure 4.4: Synergistic Digestion of the repeated DRGETGPA and SGPKTSGPKT 
peptides. Lanes 1-6 are a synergistic digestion of the repeated DRGETGPA peptide and 
lanes 7-11 show synergistic digestion of the repeated SGPKTSGPKT peptide. (1) 
DRGETGPA +MMP-9; (2) DRGETGPA +MMP-9 +50 L FAP WT lysate; 
(3)DRGETGPA +MMP-9 +25 L FAP WT lysate; (4) DRGETGPA +MMP-9 +25 L 
DPPIV lysate; (5) DRGETGPA +MMP-9 +25 L FAP S624V lysate; (6) 
SGPKTSGPKT +MMP-9 +25 L FAP S624V lysate; (7) SGPKTSGPKT +MMP-9 +25 
L DPPIV lysate; (8) SGPKTSGPKT +MMP-9 +25 L FAP WT lysate; (9) 
SGPKTSGPKT +MMP-9 +50 L FAP WT lysate; (10)SGPKTSGPKT +MMP-9.  
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Figure 4.5: Synergistic Digestion of the repeated SGPKTSGPKT peptide with 50 
L of the protease. Lanes 1-10 show the synergistic digestion of the repeated 
SGPKTSGPKT peptide. (1) SGPKTSGPKT; (2) SGPKTSGPKT +MMP-9; (3) 
SGPKTSGPKT+MMP-9 +FAP WT lysate; (4) SGPKTSGPKT+FAP WT lysate; (5) 
SGPKTSGPKT +MMP-9+DPPIV lysate; (6)SGPKTSGPKT + DDPIV lysate; (7) 
SGPKTSGPKT+MMP-9+ mGFP-N2 lysate; (8) SGPKTSGPKT+ mGFP-N2 lysate; (9) 
SGPKTSGPKT + MMP-9+FAP S624V lysate; (10) SGPKTSGPKT +FAP S624V 
lysate. 
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Chapter 5 
 
Heterodimerization between FAP and DPPIV 
Important for Proteolytic Function 
5.1: Introduction  
The tumor microenvironment is a connection between the stroma and tumor. 
There are many the complex networks of interactions and regulation signals exiting 
between the stroma and tumor. The association of those areas is important for 
oncogenesis and tumor progression.  Recently, the understanding of a tumor within 
tumor stroma components have not been wildly studied, especially protease activity in 
there that promoting extracellular matrix degradation and leading to metastasis of the 
tumor. A membrane-bound serine protease such as FAP has high expression only in 
tumor stroma and has unique substrate preferences (1-3). For development of FAP-
activated therapeutic strategies to target the release of cytotoxic compounds within the 
tumor stroma, understating the mechanisms and functions of FAP and FAP complex 
formation will represent potential targets for cancer therapy.       
Fibroblast activation protein, alpha (FAP) is a member of the S9B prolyl 
oligopeptidase subfamily containing proteases such as DPPIV, DPP8 and DPP9 (4). 
Among all enzyme members, mostly 50% of FAP amino acid shares closely relating to 
DPPIV (5). FAP and DPPIV can form a heteromeric complex with each other and be 
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important for modulating the growth, differentiation, adhesion, and metastasis of tumor 
cells (6). The DPPIV/FAP heterodimer has been found on the surface of migratory 
connective tissue cells and support cell migration that is important for connective tissue 
repair (7, 8). The hetromeric complex between FAP and DPPIV might be associates 
with proteolytic, adhesive and signal capabilities as in the model of a FAP complex 
developed by Kelly, 2005(6). FAP dimer can form a complex with DPPIV dimer and 
other cell surface molecules such as 1 integrin and uPAR (7-9) and promote matrix 
degradation, tumor growth and angiogenesis. However, the mechanism how theses 
protease form complex and promote their protease activity is still unclear.  
Both FAP and DPPIV are membrane-bound glycoproteins containing TM 
domain that might be associated with dimerization in cell membrane. Here, we 
investigated whether TM domains of FAP and DPPIV play a crucial role in 
heterodimerization by using the DN-AraTM assay. This assay was developed by Su and 
Berger in 2013 for quantifying heterdimerization relative to homodimerization (10). 
DN-AraTM assay uses co-expression between a chimera containing wild-type AraC and 
a chimera containing a mutant AraC
*
 that is unable to activate gene transcription to 
determine competition between homodimerization and heterodimerization. Reduction of 
the level of green fluorescence (GFP) reporter gene transcription this assay was 
developed for the membrane represents quantity of heterodimerization relative to 
homodimerization. Although, the assay was developed for membrane proteins that have 
a type I orientation, we inverted FAP and DPPIV TM sequences that have a type II 
orientation to fit in the system. Moreover, we also observed heterodimerization between 
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FAP and DPPIV in the intact full-length proteins. The full-length FAP and DPPIV in 
HEK293T were co-transfected in HEK293T. Immunoassay and co- 
immunoprecipitation are techniques for interpreting heterodimerization between these 
proteases.         
5.2: Material and Methods 
5.2.1: Materials  
The backbone plasminds; MBP-HA-AraC containing ampicillin resistance, 
MBP-HA-AraC
*
 containing kanamycin resistance and AraBAD:: eGFP containing 
spectinomycin were donated from Dr Pin-chuuan Su. The oligonecleotide primers were 
ordered from Integrated DNA Technologies, Inc (IDT). The Human Embryonic Kidney 
(HEK) 293T/17 cells were purchased from American Type Culture Collection (ATCC). 
DMEM was supplied from Mediatech, Inc (Corning Subsidiary). Fetal bovine serum 
was from GE healthcare life sciences. Lipofectamine 2000 was obtained from Life 
Technologies. All restriction enzymes were purchased from New England BioLabs. 
QuickChangeII site directed Mutagenesis kit for deletion mutagenesis was from Agilent 
technologies. EZ-Link™Sulfo-NHS-Biotion and Streptavidin Magnetic Beads were 
purchased from Themo scientific. The Purified HA.11 Clone 16B12 Monoclonal 
Antibody was purchase from BioLegend.  Biomax Light Film was from Carestream 
Health, Inc. All chemicals for preparing all buffers were obtained from Alfa Aesar, 
Sigma-Aldrich, J.T Baker Chemical, CalBiochem and Amresco. 
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5.2.2: Methods 
5.2.2.1: Subcloning FAP TM and DPPIV TM and DN-AraTM assay 
 FAP and DPPIV are typeII transmembrane proteins. Their N-terminus is exited 
in the cytosol. To subclone FAP TM and DPPIV TM into the backbone plasmids; MBP-
HA-AraC containing ampicillin resistance (pAraTM wt) and MBP-HA-AraC
*
 
containing kanamycin resistance (pAraTMDN), the TM sequences of FAP and DPPIV 
were inversed to be opposite orientation before inserting into the backbone plasmids. 
Overlapping oligonucleotide primers for the FAP TM and DPP TM   synthesis were 
designed using Oligoperfect
TM
 program (Invitrogen). The FAP TM and DPPIV TM 
inversed sequences contain the SacI and KpnI restriction sites because of using forward 
primer containing SacI and reverse primer linking with KpnI. Moreover we also added 
type-2 polyproline linker into N-terminus of FAP TM and DPPIV TM because a short 
cytoplasmic tail has an effect to DN-AraTM assay. The oligonucleotides and primers 
for synthesizing the inverse FAP TM and DPPIV TM are shown in Table 5.1. Unless 
otherwise stated, standard molecular biology techniques were used. All constructs were 
verified by DNA sequencing (GeneWiz).    
 pAraTMwt, pAraTNDN and pAraGFPCDF plasmids were obtained from Dr. 
Su. Plasmids were generated as described previously (10, 11). The inverse FAP TM and 
DPPIV TM domain were cloned as SacI/KpnI fragments. For pAraTMwt, those 
fragments were cloned in-frame as fusions with MBP and AraC and for pAraTMDN, 
those were cloned in-frame as fusions with MBP and AraC
*
. Plasmids pAraTMDN, 
pAraTMwt, and pAraGFPCDF were co-transformed into the AraC-deficient E.coli 
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strain SB 1676 (The E.coli genetic stock center at Yale University) and the assay was 
processed as described previously (10).  
5.2.2.2: Integration into inner membrane of E.coli of AraC chimera and 
immunoblotting 
 Because of maltose-binding protein (MBP) fusion in an N-terminus of each 
chimera containg a signal peptide to directs protein insertion into cell membrane, all 
chimera that have proper integration can grow in a maltose M9 plate under 37 
o
C for a 
couple days. Immunoblotting was carried out as described previously in the chapter 2 to 
represent expression level of each chimera using anti-myc (cell-signalling), anti-HA 
(cell-signalling) and anti-MBP (New England BioLab) monoclonal antibodies.        
5.2.2.3: Subcloning FAP full-length and DPPIV full-length gene and deletion 
mutagenesis 
The full-length FAP was amplified with the forward primer containing SacI and 
the reward primer containing KpnI and HA tag then; it was cloned into mGFP-N2 
plasmid as described in the chapter 2. The DPPIV full-length was amplified from 
human 6156880 pCMV_sportT6 (ATCC) by using the DPPIV forward primer containg 
BamHI and the DPPIV reward primer containing XhoI and HA site. Then, the purified 
PCR fragment was cloned into pcDNA3.1/V5-His-TOPO (Invitrogen). The deletion 
mutants to remove the stop codon from the full-length DPPIV were generated following 
QuickChangeII site directed Mutagenesis kit’s instruction. Therefore, the full-length 
DPPIV protein contains HA-tag, V5 epitope and His-tag after deleting stop codon. 
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Table 5.1 Oligonucleotides and primers 
 
5.2.2.4: Co-transfection and  expression in HEK293T  
The full-length FAP in mGFP-N2 Plasmid and the full-length DPPIV without 
stop codon in pcDNA3.1/V5-His-TOPO were co-transient transfected in HEK293T 
cells by using Lipofectamine2000, according to the manufacturer’s instructions. Each 
chemical-transfection was carried out on a 6-well plate with 1:1 of each plasmid. For a 
mock control, mGFP-N2 and pcDNA3.1/V5-His-TOPO was co-transfected. We also did 
transfection only mGFP-N2 to use as another control to determine by fluorescence 
microscope transfection efficiency. Cells were collected after it was incubated in 37
o
C, 
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5% CO2 incubator for 48 hours. Then cells were washed with 1X PBS and lyzed with 
1X RIPA buffer (20 mM Tris pH7.5, 150 mM Nacl 1 mM EDTA, 1 mM EGTA, 1% 
NP-40, 1 mM -glycerolphosphate, 2.5 mM Sodium pyrophosphate) without serine 
protease inhibitors on ice for 15 mins, centrifuging and collecting the supernatant as a 
cell lysate.   
5.2.2.5: Immunoblotting Assay 
 For immunoblotting of the full-length FAP wild type and the full-length DPPIV 
co-expression in HEK T cells, cells were collected after co-transfection for 48 hours. 
The cell lysate was mixed with 5X Lammeli sample buffer containing -
mecaptoethanol and heated for 10 minutes. Samples were loaded into 8% SDS- 
acrylamide gel and run in SDS running buffer with 140 V for 1.5 hours. Proteins in the 
gel were transferred with 200 A to a nitrocellulose membrane (Amersham Biosciences 
Hybond ECL) for 90 minutes. After the transferred membrane was blocked with 5% milk 
in TBST for 1 hour at room temperature, it was incubated with 1:1,000 dilution of anti 
HA monoclonal antibody (BioLegend) in incubator shaker at 4
o
C overnight and 1:1,000 
of the secondary mouse IgG antibody (NEB) at room temperature for 1 hour. After 
incubating the membrane with a chemiluminescent substrate (GE) in dark for 5 minutes, 
it was exposed with an autoradiography flim (Carestream Kodak BioMax light film) 
and developed using film processor for X- ray machine (SRX-101A, Konic Minolta). 
Both HA-tag and His-tag reveal in the full-length DPPIV expressed protein after 
removing the DPPIV stop codon. Therefore, 1:5,000 dilution of HIS monoclonal 
antibody (Cell signalling) was used to detect DPPIV expression. The transferred 
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membrane was incubated for 1 hour at room temperature and 1:5,000 of the secondary 
mouse IgG antibody (NEB) at room temperature for 1 hour. Western blotting detection 
using  chemiluminescence was described previously.  
5.2.2.6: Biotinylation and immunoprecipitation procedures  
 The co-transfected cells the full-length FAP wild type and the full-length DPPIV 
was collected and washed with 1XPBS pH 8.0 before they were resuspended at a 
concentration of ~1 × 10
6
 cells/mL in PBS (pH 8.0). EZ-Link™Sulfo-NHS-Biotin was 
used to link with a primary amino groups (-NH2) of FAP and DPPIV transmembrane 
proteins. The protocol was followed to the manufacturer’s instructions. The steps of 
both biotinylation and immunoprecipitation were described in the previous chapter. The 
supernatant containing both the full-length FAP and DPPIV transmembrane proteins 
was collected and magnetically separate from beads. The samples were run in 8% non-
denaturing gel and analyzed with western blotting against anti HA and anti HIS 
monoclonal antibody.  
5.3: Results 
5.3.1: Constructions of FAP TM and DPPIV TM  in the DN-AraTM heterodimer 
assay 
 We used a dominant-negative system as the DN-AraTM heterodimer to 
investigate a heteromeric complex between FAP and DPPIV TM domain. This system 
is based on the E.coli transcription factor AraC that can active as a homodimer at 
araBAD promoter and promotes GFP expression as a reporter in the system. Because 
the DN-AraTM heterodimer assay was developed for a type I transmembrane proteins 
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and FAP as well as DPPIV are a type II transmembrane protein that has N-terminus 
inserting into a cytosol, FAP and DPPIV sequences are inversed as shown in Figure 5.1. 
The inverse FAP TM and the inverse DPPIV TM were cloned into pAraTMwt and 
pAraTMDN plasmids, respectively (Figure 5.1B). However, we also switched to clone 
inverse FAP TM and the inverse DPPIV TM into pAraTMDN and pAraTMwt, 
respectively. The results of both should be in agreement with each other. The DN-
AraTM heterodimer assay was represented as Figure 5.2. The AraC
* 
containing chimera 
inhibit homodimerization, when the FAP TM wild-type AraC chimera (AraC) was co-
expressed with the DPPIV TM mutant AraC (AraC
*
), the formation of FAP TM and 
DPPIV TM complex was revealed as the reducing of the transcriptional activity at 
araBAD promoter. Therefore, the expression of the reporter gene GFP that was under 
control of the araBAD promoter is decreased. Both AraTM chimera contain an N-
terminal MBP fusion with a signal peptide. The results showed properly integration into 
the inner membrane of chimera because they can grow in 0.4% maltose M9 Plate as 
shown in Figure 5.3A. The expression of the FAP TM or DPPIV TM chimera 
containing either AraC or AraC
*
 was confirmed with immunoblotting with anti-HA, 
anti-myc and anti-MBP (Figure 5.3B).  
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Figure 5.1: The inverse FAP TM and DPPIV in plasmid constructs using for the 
DN-AraTM assay. (A) FAP TM and DPPIV TM sequences were designed to be 
correct direction. The start codon of FAP and DPPIV sequences connected with a linker 
will be in the AraC or AraC
*
 site. (B) pAraTMwt with amplicillin resistant containing 
C-terminal AraC wildtype and pAraTMDN with kanamycin resistant containing C-
terminal disabled AraC are the regulator plasmids using to transform to E.coli. 
araBAD::eGFP with spectinomycin resistant serves as the reporter plasmid in the assay. 
(A) 
(B) 
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Figure 5.2: The DN-AraTM assay using for investigating FAP-DPPIV 
heterodimer. Chimera containing N-terminal MBP fused to either an in-frame FAP TM 
and C-terminal AraC or an in-frame DPPIV TM and C-terminal disabled AraC that 
cannot activate transcription at araBAD promoter was expressed and regulate GFP 
expression that is under a control of araBAD promotor. Once expressed, MBP with 
signal peptide directs integration of chimera into the inner membrane of E.coli. 
Homodimerization of FAP TM can bring the AraC transcription factor in close 
proximity and activate GFP gene expression. Whereas homodimerization of DPPIV or 
heterodimerization between FAP TM and DPPIV TM domains has inability to promote 
GFP expression because of containing C-terminal disabled AraC (AraC
*
). Therefore, if 
FAP TM has a high affinity to heterodimerize with DPPIV TM, a reduction of intensity 
of GFP signal will be observed. 
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Figure 5.3: Expression of FAP TM and DPPIV TM in chimera. (A) Ara TM 
chimera with homodimeric FAP TM-cyto construct or DPPIV TM-cyto construct 
containing either HA-tag and Myc-tag were expressed in MBP-deficient MM39 cells, 
streaked onto 0.4% maltose M9 plate and incubated in 37 
o
C for two-three days. The 
growth of both HA-tag and myc-tag constructs shows properly integration into the inner 
membrane of E.coli. (B) Immunoblotting of whole-cell lysate with anti-HA, anti-Myc 
and anti-MBP monoclonal antibodies indicates that the chimera are expressed at their 
expected molecular masses. Both chimera of FAP and DPPIV have the expected size 
approximately 67 kDa)   
 
(A) 
(B) 
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5.3.2: Heterodimerization of FAP TM and DPPIV TM  
 The results from the DN-AraC assay were interpreted in the term of normalized 
GFP intensity per cells. As the previous studies (chapter 2) FAP TM domain can form a 
homodimer through a conserve small-X3- small motif. When FAP TM was expressed as 
fusion to wild type AraC, a homodimer was observe. No GFP expression when FAP-
AraC
*
 was co-expressed with DPPIV-AraC
*
 indicated that the DN-AraTM assay is a 
dominant-negative assay to investigate heterodimerization. Therefore, if preferential 
heterodimerization between FAP TM and DPPIV TM occurs, the level of GFP 
expression will reduce. As shown in the Figure 5.4, when FAP-AraC
*
 was co-expressed 
as a competitor to FAP-AraC, significant decrease in GFP expression is observed. This 
result was in agreement with when DPPIV-AraC
*
 was co-expressed as a competitor to 
DPPIV-AraC. They were used as a control to show that FAP-AraC
*
 and DPPIV-AraC
*
 
can compete with FAP-AraC and DPPIV-AraC. Therefore, a significant decrease in 
GFP intensity observed when DPPIV-AraC
*
 was co-expressed as competitor to FAP-
AraC show the preferential FAP heterodimerization with DPPIV relative to 
homodimerization. This result is consistent with the result of when FAP-AraC
*
 was co-
expressed as competitor to DPPIV-AraC. It can indicate that TM domain contribute to 
formation of heteromerization between FAP and DPPIV.   
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Figure 5.4: DN-AraTM results for heterodimerization between FAP TM and DPPIV 
TM. The results presented normalized GFP signal from pTrc without TM domain. The 
result of FAP/DPPIV* is consistent with the result of DPPIV/FAP
*
. FAP TM has an 
affinity to heterodimerize with DPPIV and a reduction in GFP was observed because of 
inability of heterodimers containing TM domain-fused AraC* to activate transcription 
at the araBAD promoter. 
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5.3.3: Expression, co-transient expression of the full-length FAP and the full-length 
DPPIV and their localization into the cell membrane 
 Due to both the full-length FAP and the full-length DPPIV have HA-tag in the 
end of protein sequences and the expected molecular masses of the full-length FAP and 
the full-length DPPIV are not much different in a monomer form. It is around 97 and 93 
kDa for a FAP monomer and DPPIV monomer, respectively. To investigate 
heterodimeric form between FAP and DPPIV, the different tag for immunoblotting 
detection is required. The full-length DPPIV that is in pcDNA3.1/V5-His-TOPO was 
deleted the stop codon so that the protein expression will be continued until reaching the 
stop codon of the parent plasmid. Therefore, the full-length of DPPIV contains HA-tag, 
V5-epitope and His-tag. The full-length FAP and the full-length DPPIV were expressed 
in HEK293T cells and immonoblotting of the whole cell lysate with anti-HA for the 
full-length FAP and anti-His for the full-length DPPIV indicate the correct molecular 
masses of those proteases (Figure 5.5). The full-length FAP and the full-length DPPIV 
was co-transient expressed in HEK293T cells in 1:1 ratio of each chimera plasmid and 
their localizations into the cell membrane were observed by using biotinylation assay. 
The Western blotting with anti-HA monoclonal antibody shown in Figure 5.6A cannot 
indicate the heterodimeric protein band of FAP and DPPIV. The expression of DPPIV 
without stop codon was quite poor. This result should be confirmed from a western 
blotting with anti-His monoclonal antibody. Comparing with the the expression of FAP 
from biotinylation, the low level of DPPIV expression in cell membrane was observed. 
We assumed that the problem of the DPPIV expression might come from the plasmid 
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construct because the protein expression from DPPIV within mGFP-N2 was higher than 
getting from DPPIV without stop codon within pcDNA3.1/V5-His-TOPO. 
 
 
 
Figure 5.5: The full-length FAP and DPPIV expression in HEK293T cells. The 
western blotting was done against HA monoclonal antibody for FAP and His 
monoclonal antibody for DPPIV. The protein molecular sizes both monomers and 
dimers were found. DPPIV dimer and monomer are 130 and 93 kDa, respectively. FAP 
dimer and monomer are 170 and 97 kda, respectively.    
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Figure 5.6: Co-transient expression between the full-length FAP and the full-
length DPPIV and localization into cell membrane. (A) The western blotting with 
anti-HA monoclonal antibody to detect the co-expression between FAP and DPPIV 
constructs. 4 ug and 2 ug of each construct in the ratio 1:1 were co-transfected into 
HEK293T. (B) Western blotting with anti-HA monoclonal antibody of biotinylation 
assay showed the protein expression in cell membrane and the remained protein in 
cytosol.   
(A) 
(B) 
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5.4 : Disscussion and the further work 
 The tumor growth and matrix degradation require the protease complex 
including matrix metalloproteases, and serine proteases in the process to exhibit EMC 
degradation and drive metastasis of tumor cells (6). FAP and DDPIV are the serine 
proteases that form the complex and localize on invadopodia that is the membrane 
protusions using to degrade extracellular matrix (9, 12). FAP and DPPIV can form 
heteromeric complex each other (8, 13). The formation of the FAP-DPPIV complex 
plays an important role for cell migration on the collagen substrate (8). This evidence 
suggested that cooperation between these two proteases might provide efficiency of 
substrate degradation and its consequent biological functions. However, how to form 
the complex between FAP and DPPIV is poorly understood. Our results from the DN-
AraTM can indicate only that the part of TM domain of both FAP and DPPIV formed 
heterodimerization. There is no preference between homodimerization and 
heterodimerization between FAP and DPPIV. This is the first evidence to indicate that 
the TM domains of these two enzymes might be promising region to drive the formation 
of the FAP-DPPIV complex. However, we still lack evidence to show that whether TM 
domains of both proteases have important role in heterodimerization in the full-length 
proteins and have any effect to their matrix degradation function. The detail of this 
further work is described more detail in chapter 7.  
 Besides the TM domain of FAP, a seven-bladed  propeller domain sitting on 
the top of a  hydrolase domain is interesting domain that could be important for 
forming complex between FAP and DPPIV. As shown in the complex formation 
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between 1 integrin and urokinase plasminogen activator receptor (uPAR), a -
propeller domain in the 3 chain of 1 integrin binds to uPAR (14). This binding 
indicates that -propeller domain can mediate complex formation between cell-surface 
molecules. Therefore, -propeller domain might also be able to mediate the complex 
formation between FAP and DPPIV as well.            
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Chapter 6 
 
BAR Domain and Membrane Biosensor for 
Drug Delivery System 
6.1: Introduction  
Development of drug delivery systems for cancer treatment has attracted 
scientists for decades. Creating detection systems and specific treatments against only 
targeted cancer cells without damaging normal cells is still a challenging task for drug 
delivery development. Scientists have proposed producing a novel membrane-based 
biosensor and drug delivery system to identify and treat cancer cells; here, we design a 
biomimetic, low-cost biosensor with  is an intricate link between the biological signal 
input (ligand binding) and biomechanical signal output (membrane curvature). BAR 
(Bin/Amphiphysin/Rvs) domains found in several membrane proteins have a dimeric 
module with a membrane-binding face. They are believed to stabilize membranes by 
forming an intrinsic curvature when they are induced with a specific ligand and formed 
into dimers (1). Therefore, they can act as sensors of membrane curvature. F-domains 
and I-domains are a sub-family of the BAR superfamily of membrane bending proteins. 
F-BAR proteins are involved in the driving or sensing of extreme positive membrane 
curvatures, while IBAR proteins bind membranes and induce negative membrane 
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curvature. This study focuses on the IBAR domain because there is less evidence 
showing applications of this protein domain as a biosensor. 
We propose to use these properties of the BAR protein as a unique, label-free 
signal in biosensing systems. We are interested in incorporating membrane protein in 
the lipidic cubic phase (LCP) to develop a membrane-based biosensor system. LCP was 
used in many biosensor applications because of its long term stability and 
biocompatibility (2). Most of the cubic phase formed from membrane lipids are 
bicontinuous cubic structures with continuous regions of both polar (water) and 
nonpolar (hydrocarbon) components. This form allows for the transport of both 
hydrophilic and hydrophobic substrates through the crystal (3). The curvature of the 
aqueous LCP channels can be reduced through the binding of the LBD (ligand binding 
domain) of BAR to the membrane. This membrane binding drives a phase transition 
from lipidic cubic phase to lamellar phase. The change of phase can be measured by 
employing FT-IR and X-ray diffraction. Therefore, we can provide a novel integrating 
technique for the biosensor assay using these targets 
 
6.2: Material and Methods 
6.2.1: Materials 
All chemicals for preparing all buffers were obtained from Alfa Aesar, Sigma-
Aldrich, J.T Baker Chemical, CalBiochem and Amresco. All restriction enzymes were 
purchased from New England BioLabs. 
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6.2.2: Methods 
6.2.2.1: Cloning of the MBP-IBAR constructs for protein expression  
An IBAR gene fragment was synthesized by PCR using IBARBamHIF and 
IBARXhoIR primers. The PCR was performed in a total volume of 40 µL, with the 
mixture containing 20 µM of each primers, 1X GoTaq Green Master Mix (New 
England BioLabs) and 6 µL IBAR p53 in pUC57 (GenScript). Amplification cycles 
were: one 5 minute cycle at 95 
o
C, 30 cycles of 95 
o
C for 30 seconds, 59 
o
C for 1 minute 
and 72 
o
C for 2 minutes, then 10 min at 72 
o
C. The PCR was then digested for one hour 
in the presence of BamHI and XhoI and run on a TBE gel, and the fragment of 
interested was gel-puified via a method adapted from Li et. Al.’s purification from 
agarose gel slices, using 4M guanidine thiocyanate in place of 6 M sodium iodide (4). 
The digested insert was ligated into pET42-MBP plasmids cut with BamHI and XhoI. 
This plasmid was donated by Logan MacDonald. Then, transformation into DH5α 
competent cells was performed via electroporation using a 1.8 kV pluse. Sequencing 
was confirmed by the University of Pennsylvania’s DNA sequencing Facility. The MBP 
– IBAR plasmids were transformed into BL-21 competent cells for gene expression 
experiment. The expression plasmids were selected using Kanamycin. 
6.2.2.2: Expression and Purification of recombinant the MBP-IBAR protein 
The MBP-IBAR transformants were grown in 150 mL LB medium (Alfa Aesar) 
at 18 o C and 200 RPM until the OD600 reached five to six. Then the cells were 
induced with 1 mM IPTG (GoldBio.com) and the culture was further incubated under 
the above condition for 12-16 hours. The cell palates were collected by centrifugation 
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and lysed by sonication in lysis buffer [50 mM Hepes (Alfa Aesar) pH 7.4, 200 mM 
NaCl (Alfa Aesar), 10 mM imidazole (Sigma), 1 mg/mL lysozyme (CalBioChem) and 1 
mM PMSF (Alfa Aesar)]. The obtain MBP-IBAR was purified following IMAC 
method as described previously. For immunoblotting, a His-tag (27E8) mouse mAb 
(Cell Signaling) was used as the primary antibody and was incubated with the 
membrane overnight (1:1000 dilution). Then Anti-Mouse IgG, HRP-linked Antibody 
(Cell Signaling) served as the secondary antibody and incubated with the membrane for 
1 hour. The blot was washed three times with TBST and developed with the ECL Plus 
Western Bloting Detection System (GE Healthcare).   
6.2.2.3: Liquid crystalline phase formation 
Approximately 5 mg of monoolein (Sigma, USA) was mixed with various 
concentrations of water to form lipid phase. The concentrations between lipid and water 
to form lipidic phase are shown in the table 6.1. The mixture was incubated at 30
o
C for 
overnight. To identify the change of membrane curvature with MBP-IBAR protein, 
soluble IBAR protein was added instead of water in the same amount. Then, the 
samples were also incubated at 30 
o
C for overnight.  
6.2.2.4: FT-IR characterization to identify liquid crystalline phases 
Fourier-transform infrared (FT-IR) spectra were recorded with a Bruker IFS 66 
spectrometer (Thermo Scientific Nicolet iS10, USA), and 16 scans were collected and 
Fourier transformed to obtain a spectral resolution of 4 cm-1. Samples of the lipid 
phases were placed on the crystal surface where the laser shines on. Bands of the 
spectra were performed using OMNIC software. 
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6.3: Results 
6.3.1: The MBP-IBAR protein expression in E.coli system 
 The MBP-IBAR was expressed in BL-21 E.coli. The expected protein size 
approximately 73 kDa was identified as shown in 12% protein gel and it was confirmed 
in the western blotting against anti-His monoclonal antibody (Figure 6.1A, B). The 
purified MBP-IBAR was used to bind the lipid phases in the following step.  
6.3.2: FT-IR spectral Features  
 FT-IR spectroscopy was used as one of tools to reveal molecular interactions 
between different lipid phases in the membrane. This experiment focuses on identifying 
the conformational change between lipidic cubic phase and lamellar phase. As shown in 
the figure 6.2, three different points obtained from infrared spectra are interesting, (1) 
C-H aliphatic stretching at 2800-1900 cm
-1
; (2) C-H bending at 1300-1400 cm
-1
; (3) C-
O stretching and O-H deformation vibration at 1000-1200 cm
-1
. We applied this 
technique to detect the conformational change from synthesized lipidic cubic phase to 
lamellar phase when IBAR binds to the cubic phase. However, IBAR is in soluble 
liquid, so adding more liquid in lipid cubic phase affects conformational change of lipid 
(Figure 6.3). We added IBAR solution instead of water and allowed it to form different 
lipid phases as shown in the table below. The MBP-IBAR concentration is measured 
using BCA protein assay kit. The purified protein is around 774 g/mL. However, low 
concentration of IBAR cannot affect conformational change of cubic phase.  
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Figure 6.1. MBP-IBAR expression. (A) 12% SDS-PAGE shows Lane 1= the MBP-
FAPS in lysis buffer and Lane 2 = Purification of the MBP-FAPS by using a Ni
2+
 
gravity column (IMAC column). (B) Western blot analysis with a HA-Tag (6E2) mouse 
mAb (HRP-Conjugated). The expected protein size of the IBAR domain linked with the 
MBP gene is approximately 73 kDa. 
 
 
 
 
 
(A) (B) 
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Figure 6.2. Difference between intrafrared spectra of lipicdic cubic phase (water: 
MO; 30:70) and lamella phase (water: MO; 10:90). As shown in each blue circle and 
red arrow, C-H aliphatic stretching , C-H bending and C-O stretching and O-H 
deformation vibration can be obtained from 2900-2800 cm-1, 1400-1300 cm-1 and 
1200-1000 cm-1, respectively. 
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Figure 6.3. Lipid phase formation based on weigh percent of water component. 
The red arrow shows the temperature (30
o
C) used in the experiment 
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Figure 6.4. Biosensor design based on membrane curvature. Dimerization of BAR 
domain activates a membrane curvature sensing domain (BAR orange). Binding of 
BAR dimer to the membrane with reduces the principle curvature (c), driving a phase 
transition from lipidic cubic (c>0) to lamellar (c=0). 
 
 
 
 
 
111 
 
 
6.4 : Further work and Discussion 
Difference in those three points from infrared spectra was not found.. 
Concentration of protein might affect to the phase transition. Amount of protein during 
0.4 -1.7g is too low. Increasing concentration of protein is in progress. It should be 
increased to be at least 5%wt (5) as following table 6.1. 
Table 6.1. The concentration between lipid and water to form the lipid phase 
% lipid &wat Lipid (MO) Water Protein 
concentration 
(IBAR) 
90% lipid, 10% water 
(lamellar phase) 
5 mg 0.56 uL (0.56 mg) 0.43 ug 
85% lipid, 15% water 
(lamellar phase) 
5 mg 0.88 uL (0.88 mg) 0.68 ug 
80% lipid, 20% water 
(transition between 
phases) 
5 mg 1.25 uL (1.25 mg) 0.97 ug 
75% lipid, 25% water 
(cubic phase) 
5 mg 1.66 uL (1.66 mg) 1.28 ug 
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The self-assembly of lipid formation depends on component of water in percent 
weight and temperature (Figure 6.3.). Moreover, a dimensionless packing parameter has 
also an effect in the lipid assembly. This parameter was defined by the ratio /(al), 
where  is the hydrocarbon chain volume, l is the maximum effective length of the acyl 
chain, and a is the head-group area at the hydrocarbon-water interface (6). For a 
bicontinuous curve bilayer of the membrane, the packing parameter on a minimal 
surface was greater than 1 and has given by 
 
  
  
  
     
 
       
 
  Where K is given by 1/(R1R2) [R1 and R2 are the principal radii of 
curvature and R1 = - R2 for the minimal surface).The increase of the lattice spacing of 
the cubic phase showed that the absolute (K) value decreases and then a result of the 
/(al) decreases. However, if the phase shrinks, the result is reversed (7). Recently, we 
are going to focus on this parameter to identify conformational change of lipid phase 
between cubic phases and lamellar phase when IBAR protein binds to the surface of the 
lipid (Figure 6.4). X-ray diffraction is also an interesting technique used to observe 
conformational curvature change. The reflection of X-ray from certain planes in the 
liquid crystal lattice might provide molecular structure change and this information may 
70% lipid, 30% water 
(Cubic phase) 
5 mg 2.14 uL (2.14 mg) 1.66 ug 
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help to support the data from FT-IR which measures molecular interactions between 
molecules. 
6.5: References 
 
1. Bhatia, V. K., Madsen, K. L., Bolinger, P. Y., Kunding, A., Hedegard, P., 
Gether, U., and Stamou, D. (2009) Amphipathic motifs in BAR domains are 
essential for membrane curvature sensing, EMBO J 28, 3303-3314. 
 
2. Nazaruk, E., Bilewicz, R., Lindblom, G., and Lindholm-Sethson, B. (2008) 
Cubic phases in biosensing systems, Anal Bioanal Chem 391, 1569-1578. 
 
3. Carlsson, N., Winge, A. S., Engstrom, S., and Akerman, B. (2005) Diamond 
cubic phase of monoolein and water as an amphiphilic matrix for electrophoresis 
of oligonucleotides, J Phys Chem B 109, 18628-18636. 
 
4. Li, J. F., Li, L., and Sheen, J. (2010) Protocol: a rapid and economical procedure 
for purification of plasmid or plant DNA with diverse applications in plant 
biology, Plant Methods 6, 1. 
 
5. Razumas, V., Talaikyte, Z., Barauskas, J., Larsson, K., Miezis, Y., and 
Nylander, T. (1996) Effects of distearoylphosphatidylglycerol and lysozyme on 
the structure of the monoolein-water cubic phase: X-ray diffraction and Raman 
scattering studies, Chem Phys Lipids 84, 123-188. 
 
6. Israelachvili, J. N., Mitchell, D. J., and Ninham, B. W. (1976) Theory of self-
assembly of hydrocarbon amphiphiles into micelles and bilayers, Journal of the 
Chemical Society, Faraday Transactions 2: Molecular and Chemical Physics 
72, 1525-1568. 
 
7. Hyde, S. T. (1989) Microstructure of bicontinuous surfactant aggregates, The 
Journal of Physical Chemistry 93, 1458-1464. 
 
 
 114 
 
Chapter 7 
 
Summary and Future Outlook 
 
7.1: Summary 
 Several proteins that has only single-spanning TM domain are involved with the 
lateral dimerization in cell membrane to manipulate their biological functions. 
Numerous human pathological states, such as different types of cancers, Alzheimer’s 
disease, tissue dysplasias and abnormalities show the mutations that affect isolation of 
TM domain in lipid bilayers (1, 2). The mutation-induced change in structure of the 
homo- and heterodimerization either specifically inhibit biological activity of those 
proteins or ability inserting in membrane (2-4). Therefore, the understanding about 
dimerization interests researchers both from academic and medical fields. FAP is found 
as the over-expressed protein in the metastasis stage of cancer cells so it is an appealing 
target for drug development for cancer therapies. However, the evidence to understand 
about FAP TM domain relating to homo- and heterodimerization and proteolytic 
activity has been still limited so far.     
This is a first evidence to show that the FAP TM domain plays an important role 
for homodimerization, FAP exopeptidase activity and localization into cell membrane. 
Comparing on- and off-interface, the small residues (G10, S14, and A18) along interfacial 
TM of FAP and in the small-X3-small motif have an effect to FAP dimerization. These 
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small and polar residues allow the two helices to come into close proximity and 
facilitate contact between the other interfacial side chains. Consequently, 
homodimerization occurs. This results show similarly with the dimerization interface of 
GpA TM that exhibits the small-X3-small motif in the interfacial region of TM (5). 
However, only G10 mutation over-expressed in HEK293T cells had affected to enzyme 
activity and enzyme localization into cell membrane. Comparing S624V mutant at FAP 
active site that completely disrupted enzyme activity and protein trafficking, G10 
mutation might be an important residue for function and trafficking of FAP into cell 
membrane.  
 The ectodomain of FAP is also another part that is important for FAP function 
and homodimerization. The predicted bulky hydrophobic residues; W728, F724 and 
Y239 from PDB accession code IZ68 showed that theses residues are buried in FAP 
homodimer interface away from water environment. The results show that mutation in 
these residues disrupts 73.88%, 74.70% and 58.52% of enzyme activity from WT in 
W728A, F724A and Y239A, respectively. Moreover, all of mutants disrupted protein 
localization into cell membrane. It can be possible that mutations in the hydrophobic 
residues buried in FAP homodimer interface might cause a conformational change of 
FAP that have an effect to enzymatic activity and protein trafficking. Moreover, the 
hydrophobic residue might serve as the key residue for protein folding and relates to 
degradation and localization of membrane protein.      
To identify the specific FAP substrate for FAP endopeptidase activity, the 
repeated DRGETGPA and SGPKTSGPKT were synthesized and expressed in E.coli to 
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be as the specific substrates for FAP endopeptidase activity. The dimer forms of theses 
substrates were indentified from the western blotting. The cleavage results of theses 
purified substrates indicated that the 25 L and 50L of total cell lysate containing FAP 
are not enough to cleave theses substrates, although 25 L is the amount that we used in 
exopeptidaes assay. Comparing the repeated DRGETGPA, the repeated SGPKTSGPKT 
is sensitive to the lysis buffer. Therefore, the purified FAP is required. Moreover, the 
substrate in a dimeric form might require more amount of enzyme concentration for 
digestion. The variation of amount of FAP, buffer condition and the time for digestion 
might be concerned for the digestion.  
 Protease complex between FAP and DPPIV at invadopodia is important for cell 
invasion and matrix degradation. Here, we indentified that TM domain can drive 
heterodimeric complex between FAP and DPPIV. Both FAP and DPPIV can 
homodimerize. DPPIV has stronger homodimerization than FAP. However, no 
preferent heterodimerization or homodimerization can be observed from the assay.  It 
indicated that TM domain can distribute to heterodimerization between FAP and 
DPPIV but other unknown factors might be involved to promote heterodimer between 
these proteases.    
 Besides study of FAP for drug delivery application, we expressed and purified 
the BAR domain to use as a unique, label-free signal in biosensing systems. The system 
was developed by incorporating membrane protein in the lipidic cubic phase (LCP). 
The IBAR domain linked with the MBP gene in the molecular mass approximately 73 
kDa was expressed from a bacterial system for using as a membrane protein.  
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Conformational change of lipid phase between cubic phases and lamellar phase when 
IBAR protein binds to the surface of the lipid were determined by FT-IR spectral 
Features. However, we did not find any effect to the phase transition when adding 
IBAR during 0.4 -1.7g. This concentration of IBAR might be too low. Increasing 
concentration of membrane protein should be considered.  
7.2: Future Outlook 
 7.2.1: The important of interfacial transmembrane domain and ectodomain 
of the full-length FAP to form heterodimeric complex with the full-length DPPIV 
 The evidences to show the heteromeric complex between FAP and DPPIV 
relating to their coordinated function to promote the growth, differentiation, adhesion, 
and metastasis of tumor cells are still limited. Understanding of the role of FAP activity 
and FAP-complex formation with DPPIV is critical determining for the tumor growth 
and matrix degradation. In the invasion of tumor cells, protease activities occur on 
membrane protrusions called invadopodia where processes dynamic membrane 
mobility, ECM adhesion and degradation (6). An invadopodia-specific protease 
complex consisting of FAP and DPPIV has been identified in WI38 cells migrating in 
collagen gel (Figure 7.1). FAP and DPPIV form a protease complex localized at 
invadopodia of cell surface to bind gelatin and localizes gelatin degradation (7). 
 118 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1. Co-localization of FAP and DPPIV at invadopodia of WI38 cells 
migrating in collagen gels. Rectangular boxes show high magnification of 
invadopodia. Phase contrast image represents as a and a
,
. Immonofluorescent image of 
DPPIV in invadopodia labeled with TRITC-mAb E19 (b and b
,
) and FAP in 
invadopodia labeled with FITC-mAb D28 (c and c
,
). Superimposed image as d
,
 shows 
FAP and DPPIV localized at the invadopodia (7).  
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 Moreover the complex of FAP and DPPIV also binds to other surface molecules 
such as β1 integrin and uPAR. It has an evidence to show that uPAR can bind to 31 
integrin through the 3 chain (8). The FAP-DPPIV complex can form close association 
with β1 integrin and uPAR to activate cell signaling for promoting matrix degradation, 
tumor growth and angiogenesis (Figure 7.2) (9). Therefore, FAP-DPPIV complex might 
be needed to regulate tumor cell behavior and theses proteases are appealing targets for 
drug delivery designs and cancer therapies. Which parts of FAP and DPPIV important 
for this heterodimeric complex is an open interesting question. A transmembrane 
domain reveals ability not only to homo- and heterodimerize in cellular membrane, but 
also specifically regulates biological activities of cells. As the results from the DN-
AraTM assay determining heterodimerization between FAP and DPPIV, FAP and 
DPPIV TM can heterodimerize. However, that assay used and investigated only in 
partial TM domains of FAP and DPPIV. For the next step, we are interested to 
investigate heterodimeric function of TM between the full-length FAP and DPPIV. 
Moreover, theses proteases contain the large C-terminal ectodomain that also can drive 
heterodimerization between FAP and DPPIV. As structure prediction using PyMoL 
program, it indicated that -propeller domain of FAP play a role in heterodimerization 
with DPPIV (Figure 7.3). 
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Figure 7.2 Model of FAP complex formation with other proteases and surface 
molecules. The complex shows FAP dimer form heterodimerization complex with 
DPPIV dimer. The FAP complex also come closely and form connection with  integrin 
and uPAR to promote proteolytic, adhesive, and signaling capabilities (9). 
 
 
 
 
 
Figure 7.3 The structural prediction of FAP-DPPIV complex by using the PyMoL 
program. An ectodomain of DPPIV (PDB accession code 1WCY, green color) and an 
ectodomain FAP (PDB accession code IZ68, cyan and blue color) form 
heterodimerization through 7-blade -propeller domain of FAP. 
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7.2.2: Effect of FAP endopeptidase specificity on the repeated FAP substrates 
The endopeptidase activity is a unique feature of FAP. It can cleave collagen 
type I that is the key structure proteins commonly found in the extracellular matrices of 
many connective tissues in mammals (10). Moreover, it still prefer to cleave gelatin 
after either PPGP or following the sequence: (D/E/E/P)-(R/K)-G-(D/E/P)-(A/G/S/T/P)-
G-P (11) and also can cleave 2-antiplasmin after Pro12 in T9 S10 G11 P12- N 13Q14 E15 
Q16 E17 sequence  (12). These characteristics provide FAP to be a potential anticancer 
drug target. Therefore, design specific substrate is imperative to use as a tool for 
developing drug delivery system. We have designed and expressed the repeated 
substrates in the sequences; DRGETGPA and SGPKTSGPKT in bacterial cells. 
However, theses substrates were not cleaved by the lysate containing FAP enzyme. 
Following the substrate profiling of FAP, FAP requires the Gly2-Pro1 motif for cleavage 
of endopeptidase substrates. However, preferences in protein at P2
’
, P1
’
, P2, P3 and P4 
are necessary for FAP activity. As Figure 7.4, FAP strictly requires pro at P1, Gly or D-
amino acid at P1, and small residues Ser or Ala at P3, whereas it lack specificity at P4, 
P1
’
 and P2
’
 (13, 14). The FAP substrate binding model (Figure 7.5) showed 
hydrophobic S1 binding pocket that fits for the substrate containing a P1 Pro residue. 
The small residue beyond P1 helps to avoid steric clashes between the protease and the 
P3 residue side chain and P3 residue’s carbonyl group. Small residues in P3 are also 
required to reduce clashes with protease residues.            
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Figure 7.4 FAP P4-P2
’ 
substrate specificity. The amino acid preferenceunderline in 
each position at  P4-P2’ in the parental sequence of the FAP 2-AP cleavage site shows 
that Proline is required at P1 (A), Gly is needed at P2 (B), and small residues such as 
Ala and Ser are required for P3. No amino acid preference for position P4,P1
’
 and P2
’
 
(13).      
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Figure 7.5 FAP substrate binding model. A peptide with P3-P1
’
 sequence is bound to 
FAP. The surface structure of FAP (pdb accession code IZ68) was labeled with carbons 
shown as white, oxygen in red, and nitrogen in blue. The carbon atom of peptide are 
showed in yellow and the side chain of P2 (D-Ala) residues is represented in cyan (13) 
 
 As the cleavage result of the repeated DRGETGPA, no cleavage was observed 
with FAP digestion, although there are Pro at P1 and Gly at P2. However, Thr and Glu 
are in P3 and P4, respectively. The residue side chain of Thr might increase steric 
clashes with protease. As Figure 7.6, the docking model of an intracellular protein, 
SPRY2 fragment in the FAP active site represents that the substrate binding site of FAP 
has an acidic electrostatic surface. It can explain that Glu at P4 would not be tolerated.     
Therefore, negatively charged residues should be avoided in FAP substrate design. 
Moreover, the sensitive cleave in the repeated SGPKTSGPKT can suggested that the 
purity of FAP is require for determining an effect of FAP to the designed substrates.  
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7.2.3:. Construction of a Substrate Linked Bio-Gel for FAP Endopeptidase 
Activity  
 A bacterial -(1,4)-polyglucuronic acid called glucuronan has been isolated and 
identified as the sole exopolysaccharide produced by a bacteria belonging to the 
Rhizobiaceae family. An interesting property of glucuronan is its ability to form a gel in 
the presence of monovalent, divalent, or trivalent cations, depending on ionic strength 
and  polymer concentration (15). The glucuronan gel has biodregradable and 
biocompatible properties (16), therefore this gel might be potentially applied in many 
applications such as agronomy, cosmetic and therapeutic. Here, we will  synthesize 
polyglucoronic acid from Avicel PH-105 NF (FMC biopolymer) by converting the 
microcrystalline cellulose into amorphous form by dissolving in 86.2% H3PO4 (17). 
Then, we convert the generated amorphous cellulose to polyglucoronic acid via 2,2,6,6-
tetramethylpipelidine-1-oxyl radical (TEMPO)-NaBr-NaClO system as described in 
Isogai and Kato paper (18). In the term of peptide, the short amino acid peptides 
designed as specific substrates for FAP in the preliminnary experiment will be 
chemically synthesized. Both sides of the short polypeptides contain an amino group. A 
carboxyl group of polyglucoronic acid is activated with 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) such that it can couple amines and yield 
amide bonds. The glucuronan gel linked with FAP endogenous substrate (Figure 8) will 
be used to investigate endopeptidase activity of FAP and the change of fluid viscosity in 
solution containing this conjugated FAP substrate and FAP is measured. The unique 
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substrate preference and distinguishable activity of FAP, especially in a gel, might be a 
way to develop a system to target tumors.    
 
 
Figure 7.6  A Model of a Substrate Linked Bio-Gel. Polyglucuronan is linked with a 
short peptide designed for FAP specific cleavage with its endopeptidase activity. 
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